University of Pennsylvania Health System

Combined Financial Statements and Combining Supplementary Data June 30, 2023 and 2022

Page(s)

Report of Independent Auditors
Combined Financial Statements
Combined Balance Sheets
Combined Statements of Operations4
Combined Statements of Changes in Net Assets5
Combined Statements of Cash Flows
Notes to Combined Financial Statements7-41
Supplementary Combining Information
Combining Balance Sheets42-43
Combining Statements of Operations



Report of Independent Auditors

To the Trustees of University of Pennsylvania

Opinion

We have audited the accompanying combined financial statements of University of Pennsylvania Health System (the "Health System"), which comprise the combined balance sheets as of June 30, 2023 and 2022, and the related combined statements of operations, of changes in net assets and of cash flows for the years then ended, including the related notes (collectively referred to as the "combined financial statements").

In our opinion, the accompanying combined financial statements present fairly, in all material respects, the financial position of the Health System as of June 30, 2023 and 2022, and the results of its operations, the changes in its net assets and its cash flows for the years then ended in accordance with accounting principles generally accepted in the United States of America.

Basis for Opinion

We conducted our audit in accordance with auditing standards generally accepted in the United States of America (US GAAS). Our responsibilities under those standards are further described in the Auditors' Responsibilities for the Audit of the Combined Financial Statements section of our report. We are required to be independent of the Health System and to meet our other ethical responsibilities, in accordance with the relevant ethical requirements relating to our audit. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our audit opinion.

Responsibilities of Management for the Combined Financial Statements

Management is responsible for the preparation and fair presentation of the combined financial statements in accordance with accounting principles generally accepted in the United States of America, and for the design, implementation, and maintenance of internal control relevant to the preparation and fair presentation of combined financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the combined financial statements, management is required to evaluate whether there are conditions or events, considered in the aggregate, that raise substantial doubt about the Health System's ability to continue as a going concern for one year after the date the combined financial statements are issued.

Auditors' Responsibilities for the Audit of the Combined Financial Statements

Our objectives are to obtain reasonable assurance about whether the combined financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an auditors' report that includes our opinion. Reasonable assurance is a high level of assurance but is not absolute assurance and therefore is not a guarantee that an audit conducted in accordance with US GAAS will always detect a material misstatement when it exists. The risk of not detecting a material misstatement resulting from fraud is higher than for one resulting from error, as fraud may involve collusion, forgery, intentional omissions, misrepresentations, or the override of internal control. Misstatements are considered material if there is a substantial likelihood that, individually or in the aggregate, they would influence the judgment made by a reasonable user based on the combined financial statements.



In performing an audit in accordance with US GAAS, we:

- Exercise professional judgment and maintain professional skepticism throughout the audit.
- Identify and assess the risks of material misstatement of the combined financial statements, whether due to fraud or error, and design and perform audit procedures responsive to those risks. Such procedures include examining, on a test basis, evidence regarding the amounts and disclosures in the combined financial statements.
- Obtain an understanding of internal control relevant to the audit in order to design audit procedures that are appropriate in the circumstances, but not for the purpose of expressing an opinion on the effectiveness of the Health System's internal control. Accordingly, no such opinion is expressed.
- Evaluate the appropriateness of accounting policies used and the reasonableness of significant accounting estimates made by management, as well as evaluate the overall presentation of the combined financial statements.
- Conclude whether, in our judgment, there are conditions or events, considered in the aggregate, that raise substantial doubt about the Health System's ability to continue as a going concern for a reasonable period of time.

We are required to communicate with those charged with governance regarding, among other matters, the planned scope and timing of the audit, significant audit findings, and certain internal control-related matters that we identified during the audit.

Supplemental Information

Our audit was conducted for the purpose of forming an opinion on the combined financial statements taken as a whole. The accompanying combined information as of and for the years ended June 30, 2023 and 2022 (the "supplemental information") is presented for purposes of additional analysis and is not a required part of the combined financial statements. The combining information is not intended to present, and we do not express an opinion on, the financial position, results of operations, changes in net assets and cash flows of the individual companies. The supplemental information is the responsibility of management and was derived from and relates directly to the underlying accounting and other records used to prepare the combined financial statements. The supplemental information has been subjected to the auditing procedures applied in the audit of the combined financial statements and certain additional procedures, including comparing and reconciling such information directly to the underlying accounting and other records used to prepare the combined financial statements or to the combined financial statements themselves and other additional procedures, in accordance with auditing standards generally accepted in the United States of America. In our opinion, the supplemental information is fairly stated, in all material respects, in relation to the combined financial statements taken as a whole.

PricewaterhouseCoopers LLP

Philadelphia, Pennsylvania September 28, 2023

University of Pennsylvania Health System Combined Balance Sheets June 30, 2023 and 2022 (thousands of dollars)

2023 2022 Assets Current Cash and cash equivalents \$ 875.232 \$ 816,111 Patient receivables, net 1,028,058 1,012,942 Third party payer receivables 39,925 6,175 Assets held for sale 43,369 Other current assets 426,289 404,796 Total current assets 2,412,873 2,240,024 Assets whose use is limited Held by trustees 168.328 165.219 RRG\Captive 201,327 304,256 3,871,739 Designated 4,094,937 Donor-restricted investments 850,670 820,548 5,092,064 5,384,960 Investments 125,393 192,058 Property and equipment, net 5,915,043 5.949.333 Other assets 784,261 629,919 Total assets \$ 14,329,634 \$ 14,396,294 Liabilities and Net Assets Current Accounts payable \$ 291,157 \$ 291,658 Accrued expenses 951,171 1,090,645 Current portion of long-term debt 55,802 66,762 Due to the University of Pennsylvania 1,198 1,303 Liabilities associated with assets held for sale 19,046 Third party payer settlements 27,718 164.167 Total current liabilities 1,357,052 1,603,575 Long-term debt, net of current portion 2,464,585 2,541,850 Third party payer settlements, net of current portion 22,784 20,787 Due to the University of Pennsylvania 35,000 40,000 1,238,031 Other liabilities 1,188,530 Pension and postretirement benefit liability 255,169 385,261 Total liabilities 5,372,621 5,780,003 Net assets Net assets without donor restriction 8,094,975 7,761,326 Net assets with donor restriction 862,038 854,965 Total net assets 8,957,013 8,616,291 Total liabilities and net assets 14,329,634 14,396,294 \$ \$

University of Pennsylvania Health System Combined Statements of Operations Years Ended June 30, 2023 and 2022 (thousands of dollars)

	2023			2022
Revenues and other support				
Net patient service revenue	\$	8,727,443	\$	8,104,389
Other revenue and support		1,247,254		1,100,018
Total revenues and other support		9,974,697		9,204,407
Expenses				
Salaries and wages		4,263,683		4,043,481
Employee benefits		1,065,016		1,010,495
Supplies and other expenses		3,793,785		3,439,836
Depreciation and amortization		414,521		387,958
Malpractice		97,253		84,558
Interest		81,549		70,013
Perelman School of Medicine (PSOM) support		20,717		20,588
Total expenses		9,736,524		9,056,929
Excess of revenue over expenses from operations		238,173		147,478
Non-operating gain (loss)				
Investment (loss) income, net		93,270		(42,094)
Other non-operating (loss)/income, net		(456)		54,929
Gain on extinguishment of debt		-		3,398
Excess of revenue over expenses		330,987		163,711
Changes in unrealized gain/(loss) on debt investments		545		(7,021)
Transfers to PSOM and University, net		(161,920)		(159,344)
Net assets released from restrictions for capital		19,823		898
Pension and other postretirement plan adjustments		144,214		545,306
Increase in net assets without donor restriction	\$	333,649	\$	543,550

University of Pennsylvania Health System Combined Statements of Changes in Net Assets Years Ended June 30, 2023 and 2022 (thousands of dollars)

	wi	Vet assets thout donor restriction	w	et assets ith donor estriction	 Total
Net assets, June 30, 2021	\$	7,217,776	\$	889,711	\$ 8,107,487
Excess of revenue over expenses Changes in unrealized loss on investments Pension and other postretirement plan adjustments Contributions and investment income Net assets released from restrictions for Operations Capital Net realized and unrealized gain on restricted funds Transfer to PSOM and University, net		163,711 (7,021) 545,306 - - 898 - (159,344)		- - 41,242 (34,088) (898) (39,940) (1,062)	 163,711 (7,021) 545,306 41,242 (34,088) - (39,940) (160,406)
Increase in net assets		543,550		(34,746)	 508,804
Net assets, June 30, 2022		7,761,326		854,965	 8,616,291
Excess of revenue over expenses Changes in unrealized loss on investments Pension and other postretirement plan adjustments Contributions and investment income Net assets released from restrictions for Operations Capital Net realized and unrealized loss on restricted funds Transfer to PSOM and University, net		330,987 545 144,214 - - 19,823 - (161,920)		- - 55,726 (37,427) (19,823) 8,597 -	330,987 545 144,214 55,726 (37,427) - 8,597 (161,920)
Increase/(decrease) in net assets Net assets, June 30, 2023	\$	333,649 8,094,975	\$	7,073	\$ 340,722 8,957,013

University of Pennsylvania Health System Combined Statements of Cash Flows Years Ended June 30, 2023 and 2022 (thousands of dollars)

		2023		2022
Cash flows from operating activities				
Increase in net assets	\$	340,722	\$	508,812
Adjustments to reconcile change in net assets	Ψ	010,122	Ŷ	000,012
to net cash provided by operating activities				
Depreciation and amortization		414,521		387,958
Bond premium amortization		(13,554)		(16,249)
Gain on asset transaction		-		148
(Gain)/Loss on extinguishment of debt		-		(3,398)
Increase/(decrease) from changes in				
Patient receivables		(15,116)		(85,933)
Other current assets		(28,992)		(56,236)
Other assets		(119,631)		(11,870)
Accounts payable and accrued expenses		(129,088)		43,772
Estimated third party payer settlements		(168,203)		(448,196)
Due from University of Pennsylvania		(5,105)		20,536
Other liabilities		63,086		(57,662)
Pension and postretirement benefit liability		14,122		(36,506)
Net realized and unrealized (gain)/loss on investments		(51,349)		112,732
Transfers, restricted contributions and pension adjustment		(30,866)		(406,466)
Net cash provided by/(used in) operating activities		270,547		(48,559)
Cash flows from investing activities				
Net purchases of property and equipment		(420,779)		(661,816)
Purchases of assets whose use is limited and investments		(459,778)		(302,063)
Sale of assets whose use is limited and investments		820,691		854,778
Net cash used for investing activities		(59,866)		(109,101)
Cash flows from financing activities				
Repayment of long-term debt and notes payable		(54,632)		(186,003)
Proceeds from restricted contributions		48,573		21,566
Proceeds from issuance of long-term debt		16,419		125,129
Transfers and other		(161,920)		(160,406)
Net cash used for financing activities		(151,560)		(199,714)
Net decrease in cash and cash equivalents		59,121		(357,374)
Cash, cash equivalents, restricted cash and restricted cash equivalents				
Beginning of year		816,111		1,173,485
End of year		875,232	\$	816,111
Supplemental disclosure of cash flow information				
Cash paid for interest, net of amount capitalized	\$	92,144	\$	79,680
Purchases of property and equipment included in accounts payable	\$	26,073	\$	32,451
Operating cash flows for operating leases	\$	50,635	\$	49,546
Right-of-use assets obtained in exchange for lease liabilities	\$	5,955	\$	32,218

1. Organization

The University of Pennsylvania Health System (UPHS or Health System) includes the following operating entities: Clinical Practices of the University of Pennsylvania (CPUP), Clinical Care Associates (CCA), Hospital of the University of Pennsylvania (HUP), Penn Presbyterian Medical Center (PPMC), Pennsylvania Hospital of the University of Pennsylvania Health System (PAH-UPHS), Chester County Hospital and Health System (TCCHHS), Lancaster General Health (LGH), Princeton Healthcare System (PHCS) and Wissahickon Hospice of the University of Pennsylvania Health System ("Wissahickon Hospice / Homecare"). In addition, the activities of UPHS' risk retention program, supported and administered by Franklin Casualty Insurance Company (FCI), a wholly owned risk retention group and Quaker Insurance Company Ltd. (QIC), a wholly owned offshore captive insurance company (collectively referred to as RRG/Captive), are included in the combined financial statements.

UPHS and the University of Pennsylvania Perelman School of Medicine (PSOM) operate under the governance of Penn Medicine. The governing body, approved by the University, operates, oversees, and coordinates the academic, research, and clinical missions of Penn Medicine. Penn Medicine replaced the prior multiple governing boards of UPHS and the PSOM, all of which were dissolved, with this single governing board. The University (as to HUP and CPUP), CCA, PPMC, PAH-UPHS, TCCHHS, Lancaster General Health, Lancaster General Hospital, Princeton Healthcare System, and Wissahickon Hospice of the University of Pennsylvania Health System are sometimes referred to herein as the "Obligated Group." In addition, UPHS is included in the financial statements of the Trustees of the University of Pennsylvania (University), a tax-exempt organization under Section 501(c) (3) of the Internal Revenue Code.

2. Significant Accounting Policies

Presentation

The University of Pennsylvania Health System Combined Financial Statements have been prepared on the accrual basis of accounting in accordance with accounting principles generally accepted in the United States of America.

COVID-19

In January 2020, the World Health Organization declared the novel strain of coronavirus ("COVID-19") a Public Health Emergency of International Concern. The COVID-19 pandemic has caused a disruption to our nation's healthcare system. Such disruption includes reduction in availability of staffing and reductions in the availability of personal protective equipment to prevent spread of the disease during patient treatment. Generally, elective procedures were postponed by physicians and acute care facilities during the periods of peak COVID-19 activity. The Health System is monitoring developments and the directives of federal, state and local officials to determine what precautions and procedures required. On March 27, 2020, the Federal Government passed the CARES Act (Coronavirus Aid, Relief, and Economic Stimulus Act), which allotted \$100 billion dollars to healthcare providers and suppliers through Medicare reimbursements, grants and other direct federal payments, which was increased to \$175 billion through subsequent legislation. Funds totaling \$21,257,000 and \$18,654,000 were allocated and recognized as Other revenue and support on the Statement of Operations for the years ended June 30, 2023 and June 30, 2022, respectively. As of June 30, 2023, UPHS had received \$606,803,000 in advanced payments from the Centers for Medicare and Medicaid Services (CMS) Accelerated and Advanced Payments Program which is reported as current Third party payer settlements on the Balance Sheet. In April 2021, CMS began to recoup Advanced Payments against claims processed. As of September 30, 2022, UPHS has repaid CMS for the Advanced Payments in full,

while Third party payer settlements reflected \$116,304,000 in advanced payments as of June 30, 2022.

Furthermore, the CARES Act allowed employers to defer the deposits and payments of the employer's share of the Social Security taxes. As of December 31, 2022, UPHS has repaid the remaining balance of Social Security Taxes, while \$57,791,000 was deferred and recorded as other liabilities on the Balance Sheet as of June 30, 2022. UPHS recognized revenue related to the CARES Act funding based on information available at June 30, 2023 from laws and regulations governing the funding as well as interpretations issued by the Department of Health and Human Services (HHS). As these new reporting requirements are subject to change, there is at least a possibility that amounts recorded under CARES Act funding may change in future periods.

UPHS was awarded funds by the PA Department of Human Services, under Act 2 of 2022 during 2022. These funds are American Rescue Plan Act funds and are specifically for making payments to hospitals for staff retention and recruitment payments to qualified staff. The entire amount awarded, \$19,239,000, was recognized as income during 2022, Similar funds were not provided during 2023.

Use of Estimates

The preparation of financial statements in conformity with accounting principles generally accepted in the United States of America requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the combined financial statements and the reported amounts of revenues and expenses during the reporting period. Actual results could differ from those estimates. Significant estimates made by management include the valuation of alternative investments, the estimated net realizable value of patient receivables and the actuarially determined pension and other postretirement benefits, malpractice and self-insurance reserves.

Cash and Cash Equivalents

Cash equivalents consist primarily of demand deposits and money market mutual funds, which would be considered a Level 1 investment under the fair value hierarchy. Investments in highly liquid debt instruments with original maturities of three months or less when purchased are included in cash and cash equivalents. The carrying amount of cash and cash equivalents are at fair value based on quoted market prices. Operating cash equivalents and highly liquid investments that are reported as Assets whose use is limited and Investments, at fair value, are considered investments through policy and are therefore excluded from the Statements of Cash Flows.

Investments and Investment Income

Investments and assets limited as to use include assets set aside by management for future purposes, including capital improvements and self-insurance funds. Certain investments have been restricted by donors and are designated as donor restricted. The significant portion of these assets are invested in the University's Associated Investment Fund (A.I.F.), which is described in greater detail below. The remaining assets are managed in separate investment portfolios.

Realized and unrealized gains and losses on investments, other than investments in debt securities that are not held for trading, are reported as a component of excess of revenue over

expenses. The change in unrestricted unrealized gains and losses on investments in debt securities not held for trading are reported below excess of revenue over expenses. Investment income or loss, realized and unrealized gains and losses on investments of donor restricted funds are added to or deducted from the appropriate net asset category based on the donor's restriction. Depending on any donor-imposed restrictions on the underlying investments, the amount of the write down is reported as a realized loss in either net assets with donor restriction or in excess of revenue over expenses, with no adjustment in the cost basis for subsequent recoveries in fair value. There were no impairment write downs reported for the years ended June 30, 2023 and June 30, 2022.

Assets Whose Use Is Limited (AWUIL)

Assets whose use is limited are comprised of cash, investments and pledges, which are reported at fair or net realizable value. These assets include assets held by trustees under indenture agreements or self-insurance trust arrangements, assets of self-insurance captives used to settle malpractice claims, assets for other retirement benefits, assets set aside by management for future purposes, over which they retain control and may subsequently use for other purposes, and donor-restricted funds (Endowments, Specific Purpose and Plant Replacement and Expansion Funds and Contributions Receivable). Contributions receivable are recognized as increases to net assets in the period received, at their fair value, net of discounts and allowances.

Fair Value

UPHS values certain financial and nonfinancial assets and liabilities by applying the FASB pronouncements on *Fair Value Measurements*. The pronouncement defines fair value and establishes a framework for measuring fair value that includes a hierarchy that categorizes and prioritizes the sources used to measure and disclose fair value. Fair value is defined as the price that would be received to sell an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date (an exit price). The hierarchy is broken down into three levels based on inputs that market participants would use in valuing the asset or liability developed based on market data obtained from sources independent of UPHS as follows:

- Level 1 Unadjusted quoted market prices in active markets for identical assets or liabilities.
- Level 2 Unadjusted quoted prices in active markets for similar assets or liabilities, unadjusted quoted prices for identical or similar assets or liabilities in markets that are not active, or inputs other than quoted prices that are observable.
- Level 3 Unobservable inputs for the asset or liability.

Inputs broadly refer to the assumptions that market participants use to make valuation decisions, including assumptions about risk. Inputs may include price information, volatility statistics, specific and broad credit data, liquidity statistics, and other factors. UPHS is required by the pronouncement to maximize the use of observable inputs (Levels 1 and 2) and minimize the use of unobservable inputs (Level 3). UPHS considers observable data to be that market data which is readily available, regularly distributed or updated, reliable and verifiable, not proprietary, and provided by independent sources that are actively involved in the relevant market. The categorization of a financial instrument within the hierarchy is based upon the pricing transparency of the instrument and does not necessarily correspond to UPHS' perceived risk of that instrument.

Assets and liabilities are disclosed in the Notes to Combined Financial Statements within the hierarchy based on the lowest (or least observable) input that is significant to the measurement. UPHS' assessment of the significance of an input requires judgment, which may affect the valuation and categorization within the fair value hierarchy. The fair value of assets and liabilities using Level 3 inputs are generally determined by using pricing models or discounted cash flow methods, which all require significant management judgment or estimation. As a practical expedient, UPHS is permitted under the pronouncement to estimate the fair value of an investment in an investment company at the measurement date using the reported net asset value (NAV). Adjustment is required if the Health System expects to sell the investment at a value other than NAV or if the NAV is not calculated in accordance with US generally accepted accounting principles (US GAAP).

Associated Investment Fund (A.I.F.)

The A.I.F. is a diversified pooled investment vehicle available solely to the University, its affiliates and subsidiaries. The A.I.F. is invested in accordance with the investment policies set out by an Investment Board which has been appointed by the Trustees of the University. The Office of Investments is responsible for the day-to-day management of the A.I.F. including identifying, selecting and monitoring a variety of external investment managers to implement the strategic asset allocation set forth by the Investment Board. Unrestricted realized gain/(loss) and the change in unrealized gain/(loss) on investments other than debt securities that are not for trading are reported as a component of the excess of revenue over expenses. The change in unrestricted unrealized gain/(loss) from investments in debt securities that are not for trading are reported in the change in net assets, while realized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a component of the unrealized gain/(loss) are reported as a co

Investment Allocation

The following is a summary of the investments held by UPHS by asset allocation.

Short-Term (A.I.F., Investments and Pension)

Short-term investments include money market accounts and fixed income investments with maturities of less than one year. Short-term investments are valued using observable market data and are categorized as Level 1 based on quoted market prices in active markets. The majority of these short-term investments are held in a US Treasury money market account.

Equity (A.I.F., Investments and Pension)

Equity investments consist of direct holdings of public securities in managed accounts as well as mutual funds and private funds. The securities held in managed accounts, along with mutual funds are generally valued based on quoted market prices in active markets obtained from exchange or dealer markets for identical assets and are accordingly categorized as Level 1. Private funds are valued at NAV.

Absolute Return (A.I.F., Investments and Pension)

Absolute return investments are made up of allocations to private funds. The fund managers of these private funds invest in a variety of securities, based on the strategy of the fund, which may or may not be quoted in an active market. Private funds are valued at NAV.

Debt (A.I.F., Investments and Pension)

Debt investments consist of direct holdings of securities in managed accounts and private funds. Securities such as US Treasuries, held in managed accounts, are valued based on quoted market prices in active markets and are categorized as Level 1. Securities such as corporate bonds and sovereign bonds, also held in managed accounts, are valued based on quoted market prices or dealer or broker quotations and are categorized as Level 2 or in the cases where inputs are unobservable as Level 3. Private funds are valued at NAV.

Private Equity (A.I.F., Investments and Pension)

Investments in private equity are in the form of close-ended private funds. The fund managers primarily invest in investments for which there is no readily determinable market value. The fund manager may value the underlying private investments based on an appraised value, discounted cash flow, industry comparables or some other method. These private fund investments are valued at NAV.

Real Estate (A.I.F. and Pension)

Investments in real estate are primarily in the form of private funds. The fund managers of these private funds primarily invest in investments for which there is no readily determinable market value. The fund manager may value the underlying investments based on an appraised value, discounted cash flow, industry comparables or some other method. Private funds are valued at NAV.

Natural Resources (A.I.F., Investments and Pension)

Investments in natural resources are made up of private funds and securities in managed accounts. The fund managers of these private funds primarily invest in investments for which there is no readily determinable market value. The fund manager may value the underlying investments based on an appraised value, discounted cash flow, industry comparables or some other method. Private funds are valued at NAV. The securities held in the managed accounts are generally valued based on quoted market prices in active markets obtained from exchange or dealer markets for identical assets and are accordingly categorized as Level 1.

Derivatives (A.I.F., Investments and Pension)

In the normal course of business, UPHS utilizes derivative financial instruments in connection with its investment activity. Derivatives utilized by the UPHS can include futures, options, swaps and forward currency contracts and are reflected at fair value following the definition of Level 1 and 2 assets and liabilities as previously described. Investments in derivative contracts are subject to foreign exchange and equity price risks that can result in a loss of all or part of an investment. In addition, UPHS is also subject to additional counterparty risk should its counterparties fail to meet the terms of their contracts.

Investment Risk (A.I.F., Investments and Pension)

The Health System's investing activities expose it to a variety of risks, including market, credit and liquidity risks and attempts to identify, measure and monitor risk through various mechanisms including risk management strategies and credit policies.

Market risk is the potential for changes in the fair value of the UPHS's investment portfolio. Commonly used categories of market risk include currency risk (exposure to exchange rate differences between functional currency relative to other foreign currencies), interest rate risk (changes to prevailing interest rates or changes in expectations of futures rates) and price risk

(changes in market value other than those related to currency or interest rate risk, including the use of NAV provided).

Credit risk is the risk that one party to a financial investment will cause a financial loss for the other party by failing to discharge an obligation (counterparty risk).

Liquidity risk is the risk that UPHS will not be able to meet its obligations associated with financial liabilities.

Details on the current redemption terms and restrictions by asset class and type of investment are as follows:

Strategy	Redemption Terms	Redemption Restrictions
Short-term	Daily	None
Equity		
Managed accounts	Daily and semi-annually with varying notice periods	None
Mutual funds	Daily	None
Private funds (1)	Weekly to annually with varying notice periods	Lock-up provisions ranging from 0 to 5 years and side pocket investments (2)
Debt		
Managed accounts	Daily	None
Private funds (1)	Daily	None; side pocket investments (2)
Absolute return	Range from monthly to annually and close-ended funds not available for redemption	Lock-up provisions ranging from 0 to 5 years with earlier redemptions subject to redemption fee, close-ended funds not available for redemption, and side pocket investments (2)
Real estate	Close-ended funds not available for redemption	Close-ended funds not available for redemption
Private equity	Close-ended funds not available for redemption	Close-ended funds not available for redemption
Natural resources		
Managed accounts	Daily	None
Private funds (1)	Close-ended funds not available for redemption	Close-ended funds not available for redemption

(1) Private funds consist of close-ended and open-ended funds generally in the form of limited partnerships. Close-ended funds have varying remaining fund terms between 1 to 18 years.

(2) Side pocket investments represents investments designated by a manager that are not available for liquidity in an otherwise liquid fund vehicle.

Property, Equipment and Depreciation

Property and equipment are stated at cost at the date of acquisition less accumulated depreciation. Depreciation is computed on a straight-line basis over the estimated useful lives of the related assets. Useful lives range from 15 to 40 years for buildings and building improvements and 5 to 20 years for equipment. Interest cost incurred on borrowed funds during the period of construction of major capital assets is capitalized as a component of the cost of acquiring those assets.

Intangible Assets

Goodwill, representing the excess of cost over assets acquired in the 1996 statutory merger of the Presbyterian Medical Center into PPMC, was \$52,850,000. The remaining balance of \$24,888,000 is included in other assets in the accompanying combined balance sheets. This balance has remained consistent since UPHS adopted the FASB Statement 142 guidance to stop amortizing Goodwill and have Goodwill subject to impairment testing. UPHS performs an annual impairment test of the PPMC reporting unit during the second quarter of the fiscal year. The calculation compares the reporting unit's carrying value to its fair value that is calculated using a discounted cash flow approach, which incorporates market participant data. In addition to the annual impairment test, additional evaluations have been done if circumstances exist that may lead to impairment. There were no goodwill impairments during 2023 or 2022.

Long-Lived Assets

UPHS continually evaluates whether events and circumstances have occurred that indicate the remaining estimated useful life of long-lived assets may warrant revision or that the remaining balance may not be recoverable. When factors indicate that long-lived assets should be evaluated for possible impairment, UPHS uses an estimate of the related undiscounted operating income over the remaining life of the long-lived assets in measuring whether the long-lived asset is recoverable. An impairment loss on these assets is measured as the excess of the carrying amount of the asset over its fair value. Fair value is based on market prices when available, or discounted cash flows.

Deferred Financing Fees

Deferred financing fees at June 30, 2023 and 2022, totaling \$11,020,000 and \$11,319,000, respectively, are amortized using the effective interest method over the life of the related debt.

Self-Insurance

UPHS accrues for estimated risks arising from both asserted and unasserted medical professional and workers' compensation claims based on historical claims data utilized by an independent actuary.

Split-Interest Agreements

UPHS' split-interest agreements with donors consist primarily of irrevocable charitable perpetual trusts and charitable lead trusts. Assets are invested and payments are made to donors and/or other beneficiaries in accordance with the respective agreements.

Perpetual trust assets are initially valued at the current market value of the underlying assets using observable market inputs based on its beneficial interest in the trust. The initially contributed assets are categorized as a Level 3 measurement in the fair value hierarchy and are reported as investments, at fair value on the combined balance sheets and as contribution revenue on the combined statements of operations. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to donor-restricted investments, net on the combined statements of changes in net assets.

Charitable remainder trust assets, where UPHS does not serve as the trustee, are initially valued using the current fair value of the underlying assets, using observable market inputs based on its beneficial interest in the trust, discounted to a single present value using current market rates at the date of the contribution. The initially contributed assets are categorized as Level 3, and reported as Investments, at fair value on the combined balance sheet and as contribution revenue on the combined statements of operations. Subsequent valuation follows this same approach with changes in fair value reported as an adjustment to donor-restricted investments, net on the combined statements of changes in net assets.

Net Assets

Net assets are classified for accounting and financial reporting purposes into two net asset categories according to donor-imposed restrictions, if any. A description of the two net asset categories is as follows:

Without donor restrictions – includes net assets that are available for the support of operations and whose use is not donor-restricted, although their use may be limited by other factors such as by contract or board designation.

With donor restrictions – includes net assets that are (i) subject to legal or donor-imposed restrictions that will be met by actions of UPHS and/or the passage of time, and (ii) the original values of donor restricted net assets, the use of which is limited to investment and can only be appropriated for expenditure by UPHS in accordance with the Pennsylvania Uniform Principal and Income Act (Pennsylvania Act).

Interest Rate Exchange Agreements

The Health System enters into interest rate swap agreements to synthetically modify the interest rate terms of its long-term debt. The agreements are not entered into for trading or speculative purposes. Fair value of interest rate swap agreements are obtained by quotes from Merrill Lynch, which is based on the income approach that uses observable market data to discount future net payment streams. The quote provided by Merrill Lynch also represents the amount the Health System would accept or be required to pay to transfer the agreement to Merrill Lynch, or exit price as defined by *Fair Value Measurements*. The Health System verifies the reasonableness of the quote provided by Merrill Lynch by comparing it to a similar quote from a swap adviser and the results of similar observable inputs used in a pricing model. The Health System has recognized an asset of \$0 and \$110,000 and liability of \$2,246,000 and \$3,506,000 as of June 30, 2023 and June 30, 2022, respectively, which represents the fair market value of the swaps. Gains/(losses) on the interest rate swap agreements are recorded as non-operating gain/(loss) in the Combined Statements of Operations.

	Merrill Lynch/ Bank of America	Merrill Lynch/ Bank of America	Merrill Lynch/ Bank of America
Notional amount	\$ 3,140,000	\$ 3,140,000	\$ 19,525,000
Trade date	7/15/2009	1/7/2010	7/28/2006
Maturity date	8/15/2023	8/15/2023	7/1/2041
Rate:			
Receive	3.184%	2.902%	70% of 1-Month LIBOR
Pay	SIFMA	SIFMA	3.980%
Default optional termination at market value	Default by UPHS	Default by UPHS	Default by UPHS
Optional termination at market value	UPHS Only	UPHS Only	UPHS Only
Collateral threshold	AAA/Aaa = Infinite	AAA/Aaa = Infinite	AAA/Aaa = Infinite
	AA(+/-) / Aa(1,2,3) = \$40M	AA(+/-) / Aa(1,2,3) = \$40M	AA(+/-) / Aa(1,2,3) = \$40M
	A(+/-) / A(1,2,3) = \$20M	A(+/-) / A(1,2,3) = \$20M	A(+/-) / A(1,2,3) = \$20M
	A(+/-) / A(1,2,3) = \$20M	A(+/-) / A(1,2,3) = \$20M	A(+/-) / A(1,2,3) = \$20M
	A(+/-) / A(1,2,3) = \$20M	A(+/-) / A(1,2,3) = \$20M	A(+/-) / A(1,2,3) = \$20M
	BBB+ / Baa1 = \$10M	BBB+ / Baa1 = \$10M	BBB+ / Baa1 = \$10M
	BBB or below = None	BBB or below = None	BBB or below = None

Participation in Partnerships

To further its mission, UPHS participates in several partnerships. If UPHS owns less than 20%, the investment is accounted for at fair value. If there is no readily determinable fair value, UPHS has elected to use the measurement alternative. If UPHS demonstrates significant influence, the investment is accounted for using the equity method. UPHS' investments within these partnerships are recorded in Other Assets on the Combined Balance Sheets. For partnerships for which UPHS has determined are central to its operations and mission, the equity share of income/(loss) is recorded in Other Revenue. Those significant investments are summarized below.

UPHS has a 49% interest in Good Shepherd Penn Partners, a venture and strategic alliance that provides post-acute medical care in eastern Pennsylvania. The investment is accounted for by utilizing the equity method.

UPHS has a 50% interest in Lancaster Behavior Health Hospital LLC, which provides adult and adolescent inpatient care for those suffering from severe depression, anxiety, or other mood disorders. The investment is accounted for by utilizing the equity method.

UPHS has a 50% interest in Lancaster Rehabilitation Hospital which serves intensive inpatient physical rehabilitation following strokes, trauma or other healthcare problems that result in severe disabilities. The investment is accounted for by utilizing the equity method.

UPHS has a 50% interest in Physicians' Surgery Center Lancaster General LLC, which is a modern outpatient surgery center located in the city of Lancaster, Pennsylvania. The investment is accounted for by utilizing the equity method.

UPHS has a 49% interest in Virtua Penn Radiation Oncology Partners LLC, a venture and strategic alliance that provides radiation and oncology physician services in southern New Jersey. The investment is accounted for by utilizing the equity method.

All other equity income/(loss) from partnerships are recorded as a component of Investment Income, net.

In January 2023, UPHS, Tandigm Health, LLC and Independence Health Group (IHG), Inc. executed a Contribution, Exchange, and Warrant Purchase Agreement for a 26.7% interest of Class B Units in Tandigm. UPHS's contribution included \$50,000,000 in cash and an 18-Year Participation Agreement. The 18-Year Participation Agreement provides that UPHS primary care physicians will receive population health support from the Tandigm and participate in value-based opportunities through Tandigm. Tandigm issued 3-Year and 5-Year warrants that allow UPHS the right and option to purchase additional 3.35% in each respective year for a total of additional 6.7% interest in the Tandigm. IHG and UPHS also hold put and call rights whereby UPHS has a put right every five years. UPHS recognizes distributions earned under the value-based care agreements in Net Patient Service Revenue. The investment in Tandigm is accounted for using the equity method with income/(loss) from partnership recorded as a component of Non-Operating Investment Income, net.

Excess of Revenues Over Expenses

The combined statements of operations include excess of revenue over expenses. Changes in net assets without donor restriction which are excluded from excess of revenue over expenses, consistent with generally accepted accounting principles, include the change in unrealized gains and losses on investments other than trading debt securities, permanent transfers of assets to and from the PSOM other than for goods and services, net assets released from restrictions for capital, and pension related changes other than net periodic pension cost.

Transfers between UPHS entities

All significant inter-entity accounts and transactions are eliminated in combination.

Net Patient Service Revenue

UPHS reports revenues generally related to contracts with patients in which our performance obligations are to provide health care services to the patients. Net patient service revenues are recorded over time during the period our obligations to provide health care services are rendered and at the estimated net realizable amounts from patients, third party payers and others in exchange for the services received.

UPHS has agreements with third party payers that provide for payments at amounts different from its established rates. Payment arrangements include prospectively determined rates per discharge, reimbursed costs, discounted charges and per diem payments. Estimates of contractual allowances, under managed care plans, which represent explicit price concessions under ASC 606, are based upon the payment terms specified in the related contractual agreements. A summary of the payment arrangements with major third-party payers is as follows:

- Medicare: Inpatient acute care services and outpatient services rendered to Medicare program beneficiaries are paid at prospectively determined rates. These rates vary according to a patient classification system that is based on clinical, diagnostic, and other factors.
- Inpatient psychiatric services and medical education costs related to Medicare beneficiaries are paid based on a cost reimbursement methodology. UPHS is reimbursed for cost reimbursable items at a tentative rate with final settlement determined after submission of annual cost reports by each hospital and audits thereof by the Medicare fiscal intermediary.
- Medicaid: Inpatient and outpatient services rendered to Medicaid program beneficiaries are paid at prospectively determined rates. Additional amounts are allocated to each hospital for training residents and serving a disproportionate indigent population.
- Commercial: UPHS also has reimbursement agreements with certain commercial insurance carriers, health maintenance organizations and preferred provider organizations. The basis for reimbursement under these agreements includes prospectively determined rates per discharge, discounts from established charges, and prospectively determined per diem rates.

Revenue from the Medicare and Medicaid programs accounted for approximately 34% and12%, respectively, of Health System's hospital Net patient service revenue for the year ended 2023, and 33% and 13%, respectively, of the Health System's Net patient service revenue, for the year ended 2022. Laws and regulations governing the Medicare and Medicaid programs are extremely complex and subject to interpretation. As a result, there is at least a reasonable possibility that recorded estimates will change by a material amount in the near term. Certain revenue received for third party payers is subject to audit and retrospective adjustments.

Final adjustments resulting from settlements with third party payers are recorded in the year in which they are settled. The amount was an increase of \$68,954,620 and \$44,660,000 to net patient service revenue in 2023 and 2022, respectively, as a result of final settlements and the revision or removal of reserves previously estimated that were no longer necessary.

Self-Pay and Other Adjustments to Revenues

UPHS calculates implicit price concessions, or revenue adjustments, based on management's review of historic net portfolio collections, current economic conditions, historical experience, trends in health care coverage and other collection indicators. The portfolio approach combines similar classes of accounts into groups for assessment. These implicit price concessions are recorded when patient service revenues are recognized. After satisfaction of amounts due from insurance and reasonable efforts to collect from the patient have been exhausted, UPHS follows established guidelines for placing certain past-due patient balances with collection agencies, subject to terms of certain restrictions on collection efforts as determined by UPHS. Account receivables are written off after collection efforts have been followed in accordance with UPHS' policy.

Medicaid Modernization Program

On July 3, 2010, the Pennsylvania General Assembly passed the Public Welfare Code amendment (Act 49) which was signed into law by the Governor, establishing a new program referred to as Medicaid Modernization. The program was subsequently approved by the federal Centers for Medicare and Medicaid Services. The program is designed to provide additional funding to Pennsylvania hospitals for the purpose of enhancing access to quality healthcare for qualifying Medicaid beneficiaries, helping to partially mitigate the losses incurred by hospitals resulting from low reimbursement rates. To accomplish this objective, for fiscal years 2011 through 2020, the program provides participating hospitals with improved inpatient fee-for-service, hospital payments, establishes enhanced hospital payments through Medicaid managed care organizations (MCOs) and secures additional federal matching Medicaid funds through a Quality Care Assessment, under which hospitals pay the state a percentage of their net inpatient revenue. After deducting the cost of the assessment due to the state, UPHS recognized additional revenues over expenses of \$59,773,081 in fiscal year 2023 and \$71,410,000 in fiscal year 2022 from the Pennsylvania Medicaid Modernization program.

Third Party Agreements

During 2017, UPHS and Independence Blue Cross (IBC) reached an agreement on terms of a new five-year agreement and continuing unless terminated by the parties. Payments made for inpatient services provided to IBC traditional and managed care subscribers are affected on a per case rate basis for most services. Payment for outpatient services is principally based upon negotiated fee schedules. Hospital and physician rates also provide for annual inflationary increases. In addition, incentives are paid for high performance with regard to clinical outcomes and patient quality. On September 10, 2021, this agreement was extended from June 30, 2022, to June 30, 2025.

During 2015, UPHS and Aetna reached agreement on terms of a new five-year agreement. The terms of the new agreement provide payments for inpatient hospital services on a per case rate basis. Payments for outpatient services continue to be predominantly based upon negotiated fee schedules. In June of 2020, a 1-year "bridge agreement" was agreed upon beginning July 1, 2020 and continues through June 30, 2021. In 2021, a new agreement was negotiated running through June 30, 2025. The new agreement consolidated all prior existing agreements across all UPHS regions and entities. Further, extensive new value-based payment models were layered on top of the existing fee-for-service framework.

Endowments

The Commonwealth of Pennsylvania has not adopted the Uniform Management of Institutional Funds Act (UMIFA) or the Uniform Prudent Management of Institutional Funds Act (UPMIFA). Rather, the Pennsylvania Uniform Principal and Income Act (Pennsylvania Act) governs the investment, use and management of the UPHS' endowment funds. The Pennsylvania Act allows a non-profit to elect to spend between 2% and 10% of the endowment market value, determined at least annually and averaged over a period of three or more preceding years.

The Pennsylvania Act does not require the preservation of the fair value of a donor's original gift as of the gift date of a donor-restricted endowment fund, absent explicit donor stipulations to the contrary. However, based on its interpretation of the Pennsylvania Act and relevant accounting literature, UPHS classifies the following as net assets with donor restrictions for reporting purposes: (i) the original value of donated assets required to be invested in perpetuity; (ii) the original value of subsequent donated assets required to be invested in perpetuity; (iii) accumulations to the donated assets invested in perpetuity made in accordance with the direction of the applicable donor gift instrument at the time the accumulation is added to the fund; and (iv) donated assets and accumulations that are subject to legal or donor-imposed restrictions that will be met by actions of the University and/or the passage of time.

UPHS follows the University's endowment spending policy. In accordance with the Pennsylvania Act, the University has elected to adopt and follow an investment policy seeking a total return for the investments held by the A.I.F., whether the return is derived from appreciation of capital or earnings and distributions with respect to capital or both. The endowment spending policy which the Board of Trustees has elected to govern the expenditure of funds invested in the A.I.F. is designed to manage annual spending levels and is independent of the cash yield and appreciation of investments for the year. For Fiscal Year 2023, the spending rule target payout was based on the sum of: (i) 70% of the prior fiscal year distribution adjusted by an inflation factor; and (ii) 30% of the prior fiscal year-end fair value of the A.I.F., lagged one year, multiplied by 5.0% target spending rate for all funds.

3. Assets Whose Use Is Limited

Assets whose use is limited at June 30, 2023 and 2022 are set forth in the following table (in thousands):

	 2023	 2022
Held by trustees		
Short term investments		
Debt service	\$ 7,943	\$ 6,451
Capital project fund	2,623	7,095
Other	1,308	1,234
Marketable equity securities		
Other retirement programs	152,439	130,590
Other	1,500	13,229
Other	 2,515	 6,620
Total held by trustees	 168,328	 165,219
RRG/Captive		
Short term investments	201,327	245,785
Marketable debt securities	-	37,955
Marketable equity securities	 -	 20,516
Total RRG Captive	 201,327	 304,256
Designated		
Short term investments	31,557	10,867
Associated Investment Funds (A.I.F)	3,756,429	3,924,754
Marketable debt securities	24,818	119,095
Marketable equity securities	37	69
Other	 58,898	 40,152
Total designated	 3,871,739	 4,094,937
Donor-restricted		
Short term investments	47,834	46,721
Marketable debt securities	21,940	21,364
Marketable equity securities	86,397	67,080
Associated Investment Funds (A.I.F)	631,665	643,634
Contribution receivable, net	9,164	5,362
Other	 53,670	 36,387
Total donor-restricted	 850,670	 820,548
Total assets whose use is limited	\$ 5,092,064	\$ 5,384,960

4. Investments

Investments at June 30, 2023 and 2022 are set forth in the following table (in thousands):

		 2022	
US Treasury obligations	\$	125,013	\$ 124,770
Marketable debt securities		-	66,908
Other		380	 380
	\$	125,393	\$ 192,058

5. Fair Value Measurement

Investments, derivative instruments, and assets whose use is limited, measured at fair value in accordance with the Fair Value Measurements standard as of June 30, 2023 and 2022 are as follows (in thousands):

	i	oted Prices n Active Markets Level 1)	Ob	gnificant Other oservable Inputs Level 2)	Un	ignificant observable Inputs (Level 3)	 restments at NAV	Total 2023
Assets								
Short term investments Equity investments	\$	346,642	\$	-	\$	-	\$ -	\$ 346,642
US equities		132,755		-		-	-	132,755
International equities		-		-		-	-	-
Debt investments		121,840		3,173				125,013
US Treasuries and Agencies Corporate bonds		34,782		3, 173 14,405		-	-	49,187
Split-interest agreements		, _		, _		107,619	-	107,619
Absolute return		-		-		-	-	0
Natural resources		85		-		-	-	85
Private equity		-		-		-	 58,898	 58,898
	\$	636,104	\$	17,578	\$	107,619	\$ 58,898	 820,199
Associated Investment Fund (A.I.F.)								 4,388,094
Total: Assets								\$ 5,208,293

5. Fair Value Measurement (continued)

	i	oted Prices n Active Markets Level 1)	0	ignificant Other bservable Inputs (Level 2)	Ur	Significant nobservable Inputs (Level 3)	 vestments at NAV	Total 2022
Assets								
Short term investments	\$	354,921	\$	-	\$	-	\$ -	\$ 354,921
Equity investments		407 740						407 740
US equities International equities		127,712		-		-	-	127,712
Debt investments		-		-		-	-	-
US Treasuries and Agencies		87,553		37,216		-	-	124,769
Corporate bonds		101,929		149,927		-	-	251,856
Split-interest agreements		-		-		103,772	-	103,772
Absolute return		-		-		-	-	-
Natural resources		86		-		-	-	86
Private equity		-		-		-	 40,151	40,151
	\$	672,201	\$	187,143	\$	103,772	\$ 40,151	\$ 1,003,267
Associated Investment Fund (A.I.F.)								4,568,388
Total: Assets								\$ 5,571,655

Changes to the reported amounts of split interest agreements, measured at fair value using unobservable (Level 3) inputs as of June 30, 2023 and 2022 are all recorded as net unrealized gains and losses. The primary unobservable input used in the fair value measurement of the split interest agreements is the discount rate. Significant fluctuation in the discount rates utilized in this calculation could result in a material change in fair value.

As noted above, UPHS participates in the Associated Investment Fund (A.I.F). At June 30, 2023 and June 30, 2022, UPHS held 21.58% and 22.75% of the total investment fund, respectively. The asset classification for the A.I.F. is as follows (in thousands):

University of Pennsylvania Health System Notes to Combined Financial Statements June 30, 2023 and 2022

5. Fair Value Measurement (continued)

	in M	ed Prices Active arkets evel 1)	Significant Other Observable Inputs (Level 2)		Significant Unobservable Inputs (Level 3)		Unobservab Inputs		Investments at NAV		Total 2023		
Assets													
Short term investments	\$	585,274	\$	-	\$	-	\$	-	\$		585,274		
Equity investments		-		-		-		-					
US equities		319,779		-		-		1,596,609		1,	916,388		
International equities		394,339		-		-		1,297,292			591,631		
Emerging market equities		-		-				1,398,030			398,030		
Debt securities								1,000,000		1,	500,000		
US Treasuries		1,070,244								1	170 044		
		1,070,244		-		-		-		Ι,	070,244		
Sovereign bonds		-		35		-		-			35		
Absolute return		-		-		-		4,275,853			275,853		
Real assets		-		-		-		2,603,378		2,	603,378		
Private equity		-		-		4,000		7,770,858		7,	774,858		
Derivative instruments		-		2,784		-		-			2,784		
Total: Assets	\$ 2	2,369,636	\$	2,819	\$	4,000	\$	18,942,020	\$	21,	318,475		
Less: Liabilities		957,461		25,834							983,295		
	\$	1,412,175	\$	(23,015)	\$	4,000	\$	18,942,020	\$	20,	335,180		
	Qı	uoted Prices in Active Markets (Level 1)	5	Significant Other Observable Inputs (Level 2)		Significa Unobserva Inputs (Level 3	able	Investmen at NAV	ts		Total 2022		
Assets Short term investments	\$	926,047		\$	-	\$	-	\$	-	\$	926,047		
Equity investments		000.004						4 4 4 7 0			4 474 054		
		326,291			-		-	1,147,9			1,474,254		
US equities											1,503,843		
International equities		350,191			-		2	1,153,6 1 457 5			1 457 588		
International equities Emerging market equities					-		-	1,153,6 1,457,5			1,457,588		
International equities Emerging market equities Debt securities US Treasuries		350,191			-		-				1,457,588 439,890		
International equities Emerging market equities Debt securities US Treasuries Sovereign bonds		350,191 1		3	- - 2		-	1,457,5	:87 - -		439,890 32		
International equities Emerging market equities Debt securities US Treasuries Sovereign bonds Absolute return		350,191 1 439,890 - -		3	- - 2 -		- - - -	1,457,5 4,332,6	- - 505		439,890 32 4,332,605		
International equities Emerging market equities Debt securities US Treasuries Sovereign bonds Absolute return Real assets		350,191 1		3	- - 2 -	3,	- - - 547	1,457,5 4,332,6 2,469,3	87 - - - - - - - - - - - - - - - - - - -		439,890 32 4,332,605 2,565,547		
International equities Emerging market equities Debt securities US Treasuries Sovereign bonds Absolute return Real assets Private equity		350,191 1 439,890 - -			- - -	3,	- - - 547	1,457,5 4,332,6	87 - - - - - - - - - - - - - - - - - - -		439,890 32 4,332,605 2,565,547 7,851,190		
International equities Emerging market equities Debt securities US Treasuries Sovereign bonds Absolute return Real assets Private equity Derivative instruments	\$	350,191 1 439,890 - 92,601 - - -		34,68	- - 0		-	1,457,5 4,332,6 2,469,3 7,851,1	87 - 505 99 90 -	\$	439,890 32 4,332,605 2,565,547 7,851,190 34,680		
International equities Emerging market equities Debt securities US Treasuries Sovereign bonds Absolute return	\$	350,191 1 439,890 - -			- - 0 2		- - 547 - 547 - 547	1,457,5 4,332,6 2,469,3	87 - 505 99 90 -	\$	439,890 32 4,332,605 2,565,547 7,851,190		

6. Other Assets

Other assets at June 30, 2023 and 2022 are set forth in the following table (in thousands):

	2023			2022
Goodwill, net	\$	24,888	\$	24,888
Certificate of need		22,000		22,000
Other receivables		159,512		146,750
Malpractice receivable		200,145		119,795
Prepaid expenses		146,051		140,761
Inventory		121,461		118,412
Interests in non-consolidated subsidiaries		199,836		113,255
Right-of-use assets		301,126		314,714
Other		35,531		34,140
		1,210,550		1,034,715
Less: Current portion		(426,289)		(404,796)
	\$	784,261	\$	629,919

Amortization expense charged to operations totaled \$1,700,000 and \$737,000 in 2023 and 2022, respectively.

As of December 31, 2022, UPHS entered into an agreement with a local university to sell the Pennsylvania College of Health Sciences, a UPHS entity affiliated with Lancaster General Hospital. The sale is expected to be finalized during fiscal year 2024 subject to approval of applicable accreditation, and oversight from government and other bodies. The fair value of the PA College, less any costs to sell, was classified as held for sale as of December 21, 2022. Any subsequent changes in value are recorded as an adjustment to the carrying value of the assets held for sale. At June 30, 2023, the assets held for sale and liabilities related to assets held for sale, respectively, are comprised of the following:

	 2023
Other receivables Inventory Prepaid Expenses and Current Assets Property, Plant, and Equipment, net	\$ 6,347 11 1,141 35,870
Assets held for sale	\$ 43,369
Current portion of long-term debt Accounts payable Accrued payroll and related taxes Lease Liability Other Liabilities	\$ 155 1,003 1,459 14,334 2,095
Liabilities associated with assets held for sale	\$ 19,046

6. Other Assets (continued)

The intended sale of the PA College resulted in the recording of Fixed Asset impairment of approximately \$14,573,000 recognized within Other gains and losses as of 6/30/23.

7. Property, Plant, Equipment and Accumulated Depreciation

Property, plant, equipment (PPE) and accumulated depreciation at June 30, 2023 and 2022 are set forth in the following table (in thousands):

		 2022	
Land and improvements Building and improvements	\$	200,800 6,607,536	\$ 203,618 6,493,567
Fixed and movable equipment		2,873,723 9,682,059	 2,797,506 9,494,691
Accumulated depreciation		(4,076,084) 5,605,975	 (3,820,681) 5,674,010
Construction in progress	\$	309,068 5,915,043	\$ 275,323 5,949,333

Depreciation expense charged to operations totaled \$412,821,000 and \$387,221,000 in 2023 and 2022, respectively. Capitalized Interest recorded was \$7,980,000 and \$20,086,000 in 2023 and 2022, respectively.

8. Long-Term Debt

A summary of debt as of June 30, 2023 and 2022 are set forth as follows (in thousands):

		Effective		
		Interest Rate at		
	Final Maturity	June 30, 2023	2023	2022
Fixed rate debt obligations:				
Lancaster County Hospital Authority (LCHA)				
Series A of 2016 revenue bonds	August 15, 2042	1.90% - 3.52%	\$142,915	\$147,640
Series B of 2016 revenue bonds	August 15, 2046	1.86% - 3.58%	107,890	119,485
Pennsylvania Higher Education Facilities Authority (PHEFA)				
Series A of 2021 revenue bonds	August 15, 2044	1.61% - 2.11%	79,810	79,810
Series B of 2021 revenue bonds	August 15, 2042	0.82% - 2.70%	109,735	109,735
Series A of 2019 revenue bonds	August 15, 2049	1.67% - 3.22%	534,870	534,870
Series A of 2017 revenue bonds	August 15, 2047	2.60% - 3.68%	400,000	400,000
Series C of 2016 revenue bonds	August 15, 2041	1.43% - 3.08%	124,255	127,800
Series A of 2015 revenue bonds	August 15, 2045	2.22% - 4.00%	194,245	209,870
Series A of 2012 revenue bonds	August 15, 2042			8,305
New Jersey Health Care Facilities Financing Authority (NJHCFFA)				
Princeton Healthcare System Series A of 2016	July 1, 2039	2.08% - 3.88%	157,075	162,875
University of Pennsylvania Health System 2017 Taxable Bond	August 15, 2047	4.01%	200,000	200,000
Lancaster General Hospital 2015 Taxable Note	August 11, 2032	2.25%	60,453	62,518
Mortgages, Loans and other	Various	Various	95,500	96,591
Variable rate debt obligations:				
PHEFA Series A of 2008 revenue bonds	January 1, 2038	3.47%	69,995	69,995
NJHCFFA Princeton Healthcare System Series B of 2016	July 1, 2045	4.66%	65,000	65,000
NJHCFFA Princeton Healthcare System Series C of 2016	July 1, 2045	4.61%	20,000	20,000
Total outstanding bonds payable			2,361,743	2,414,494
Unamortized original issue premiums, discounts and debt costs, net			169,604	183,158
			2,531,347	2,597,652
Current portion of debt obligations			(66,762)	(55,802)
		_	2,464,585	2,541,850

Effective interest rate include the impact of amortizing premiums and discounts.

8. Long-Term Debt (continued)

On May 18, 2022, Pennsylvania Higher Educational Facilities Authority (PHEFA) issued Series B of 2021 Refunding Revenue Bonds (PHEFA 2021B bonds), which was a forward delivery, with an aggregate principal amount of \$109,735,000. The proceeds were used to fund an escrow which was used to refund \$122,275,000 from the PHEFA Series A of 2012 revenue bonds. The refunded bonds were legally defeased and are longer included among UPHS' reported liabilities.

On February 25, 2022, the University executed a commitment letter and rate-lock agreement to facilitate the extension of the Lancaster General Hospital ("LGH") 2015 Taxable Note with an aggregate principal amount not to exceed \$62,525,000. As of August 1, 2022, the LGH 2015 taxable note has been extended for a ten-year period with a maturity date of August 1, 2032, carrying the same fixed interest rate of 2.25%.

The UPHS Series B of 2021 were issued on May 18, 2022 for \$109,735,000. The entire amount of \$122,275,000 was used to defease the UPHS Series A of 2012 revenue bonds.

UPHS Series A of 2008 Bonds were issued on April 21, 2008. Interest on the bonds is reset weekly through a remarketing process. The bonds are subject to optional redemption by the University, the obligated group agent, on any scheduled interest payment date at a redemption price equal to 100% of the principal amount plus accrued interest and option tender by the Holders upon seven days' notice. The bonds are enhanced by a renewable direct pay letter of credit issued by Bank of America with an expiration date of April 15, 2028 and UPHS self-liquidity policy.

Each of the Series A, B and C revenue bonds are subject to optional redemption by the University, the obligated group agent, at a redemption price of 100% plus accrued interest on or after specified dates within the agreements.

The PHEFA, LCHA and NJHCFFA Revenue Bonds are collateralized by master notes issued under the UPHS Master Trust Indenture (MTI). The MTI and related agreements contain certain restrictive covenants which limit the issuance of additional indebtedness and among other things, require UPHS to meet an annual debt service coverage requirement of "income available for debt service" (excess of revenue over expenses plus depreciation, amortization, interest expense and extraordinary items) at an amount equal to 110% of the annual debt service requirements. If the coverage requirement for a particular year is not met, within six months of the close of that fiscal year, UPHS must retain the services of a consultant, to make recommendations to improve the coverage requirement. UPHS must also implement the recommendations of the consultant to the extent that they can be feasibly implemented. UPHS will not be considered to be in default of the provisions of the MTI, so long as UPHS has sufficient cash flow to pay total operating expenses and to pay debt service for the fiscal year. The debt service coverage requirement for 2023 and 2022 was met by UPHS. Additionally, UPHS has pledged its gross revenues to collateralize its obligation under the MTI.

8. Long-Term Debt (continued)

UPHS has \$100,000,000 line-of-credit, with a maturity on April 12, 2025, to supplement liquidity and issue letters of credit to cover balances due on construction projects and reinsurance agreements. There were no draws on or any outstanding balance on the Letter of Credit as of June 30, 2023 and June 30, 2022. Letters of credit issued under the line were \$4,971,000 and \$4,709,000 at June 30, 2023 and 2022, respectively, and are included in contingencies and commitments.

A summary of maturities of long-term debt payments for the next five years and thereafter is as follows (in thousands):

	 PHEFA	 LCHA	NJHCFFA		IHCFFA C		 Total
Fiscal Year							
2024	\$ 33,725	\$ 13,740	\$	6,090	\$	2,803	\$ 56,358
2025	45,245	5,215		6,395		2,861	59,716
2026	47,575	5,475		6,715		2,919	62,684
2027	23,440	31,520		7,050		2,979	64,989
2028	35,680	6,050		7,405		3,041	52,176
Thereafter	 1,327,245	 188,805		208,420		245,850	 1,970,320
Total principal	1,512,910	250,805		242,075		260,453	2,266,243
Unamortized original issue premiums,							
discounts, and debt costs	 137,396	 22,705		10,551		(1,048)	 169,604
Total debt	\$ 1,650,306	\$ 273,510	\$	252,626	\$	259,405	\$ 2,435,847

	N	ortgages otes and Other
Fiscal Year		
2024	\$	10,410
2025		4,556
2026		4,595
2027		4,524
2028		13,347
Thereafter		58,068
Total mortgages, notes and other	\$	95,500

9. Transactions with the University of Pennsylvania

UPHS transferred \$150,374,000 and \$148,317,000 in 2023 and 2022, respectively, to further the research and educational activities of the PSOM, including capital projects constructed by Penn Medicine on behalf of the University funded by the University totaling \$13,057,000 in 2023 and \$24,715,000, respectively. In addition, PSOM support totaling \$20,717,000 and \$20,588,000, which represents academic operating support to the clinical departments of the PSOM, has been recognized as operating expenses in 2023 and 2022, respectively. These activities are integral to the overall Penn Medicine mission and are reported as expenses and transfers in the combined financial statements.

Certain University expenses, such as a portion of the salaries of the PSOM faculty, qualify for reimbursement by third party payers. Reimbursement for these costs is claimed by UPHS and recognized as other operating revenue by CPUP and the PSOM.

Due to/(from) the University of Pennsylvania reflects the net balance resulting from transactions conducted between UPHS and the University (primarily inter-entity billings for allocation of common costs, physician salaries and benefits, certain purchased services, and support for the PSOM). UPHS transferred \$11,546,000 in 2023 and \$11,027,000 in 2022 to the University. The amounts outstanding at June 30, 2023 and 2022 represented normal current inter-entity activity.

10. Net Assets

The major components of net assets at June 30, 2023 and 2022 are as follows (in thousands):

		2023											
		thout Donor Restriction		ith Donor estriction	Total								
General operating Capital Endowment Quasi Donor restricted	\$	4,294,000 - - 3,800,975 -	\$	93,954 31,318 - - 736,766	\$	4,387,954 31,318 3,800,975 736,766							
	\$	8,094,975	\$	862,038	\$	8,957,013							
		2022											
		thout Donor Restriction	or With Donor Restriction			Total							
General operating Capital Endowment	\$	3,791,061 -	\$	81,022 27,007	\$	3,872,083 27,007							
Quasi Donor restricted		3,970,265 -		- 746,936		3,970,265 746,936							
	\$	7,761,326	\$	854,965	\$	8,616,291							

11. Net Assets with Donor Restriction

Net assets with donor restriction are those whose use by UPHS has been limited by donors for the following purposes (in thousands):

		 2022	
Specific purpose (i.e., departmental room funds)	\$	125,272	\$ 108,029
Endowment - held by others		107,619	103,772
Endowment - fair value adjustments		508,980	526,578
Endowment - original cost basis		120,167	 116,586
	\$	862,038	\$ 854,965

Changes to the reported amounts of the UPHS' endowments and split interests as of June 30, 2023 and June 30, 2022 are as follows (in thousands):

	 thout Donor Restriction	2023 With Donor Restriction	Total		
Endowments and split interests at June 30, 2022	\$ 3,970,264	\$ 746,936	\$	4,717,200	
Investment return	38,887	15,623		54,510	
New gifts	40	3,581		3,621	
Allocation of AIF assets for expenditure	(213,554)	-		(213,554)	
Other investment allocations	(4,954)	-		(4,954)	
Transfers to create Board designated funds	(25,533)	3		(25,530)	
Donor Imposed Income reinvestments	-	6,448		6,448	
Other transfers	2,598	(2,598)		-	
Released from restriction	 33,227	(33,227)		-	
Endowments and split interests at June 30, 2023	\$ 3,800,975	\$ 736,766	\$	4,537,741	

	2022											
		thout Donor Restriction		With Donor Restriction	Total							
Endowments and split interests at June 30, 2021	\$	4,073,852	\$	795,515	\$	4,869,367						
Investment return		(2,387)		(19,133)		(21,520)						
New gifts		41		1,497		1,538						
Allocation of AIF assets for expenditure		(202,869)		-		(202,869)						
Other investment allocations		(4,289)		-		(4,289)						
Transfers to create Board designated funds		73,128		1,360		74,488						
Donor Imposed Income reinvestments		-		1,548		1,548						
Other transfers		6,722		(7,785)		(1,063)						
Released from restriction		26,066		(26,066)		-						
Endowments and split interests at June 30, 2022	\$	3,970,264	\$	746,936	\$	4,717,200						

At June 30, 2023 and 2022, there were no material donor-restricted endowment funds for which the fair value of assets was less than the level required by donor stipulations or law.

12. Pension and Postretirement Benefit Costs

Retirement benefits are principally provided to active employees through a combination of qualified and non-qualified defined contribution plans (DC). The UPHS policy with respect to its DC Plan contribution is up to 6.5% of eligible employee salaries and contributions amounted to \$130,125,000 and \$114,628,000 in 2023 and 2022, respectively.

UPHS also has several non-contributory defined benefit (DB) pension plans. Benefits under the plans generally are based on the employee's years of service and compensation during the years preceding retirement. Contributions to the plans are made in amounts necessary to at least satisfy the minimum required contributions as specified in the Internal Revenue Service Code and related regulations. UPHS' primary plan was closed to new entrants effective July 1, 2010; the benefit accruals for all participants of the LGH and PHCS plans were frozen effective June 30, 2013, and December 31, 2011, respectively.

On December 31, 2022, the LGH and PHCS plans were merged into the UPHS plan with no changes to existing benefits and coverages. The pension expense for the merged plan was then remeasured as of the merger date, resulting in additional expense of \$7,025,000 for the year ended June 30, 2023, due to higher interest cost and a lower expected return on plan assets for the combined plan. Plan assets for LGH and PHCS of \$613,825,000 and \$121,857,000, respectively, were transferred to centralized UPHS plan.

Additionally, UPHS provides healthcare and life insurance benefits (Other Postretirement Employee Benefits or OPEB); while LGH provides only life insurance for retirees prior to January 1, 2012. Only a limited number of employees may become eligible for such benefits if they reach retirement age while working for some UPHS entities. These and similar benefits for active and certain retired employees are provided through insurance contracts.

UPHS uses a measurement date of June 30 for their defined benefit and postretirement health care benefit plans, whereas LGH and PHCS are on a calendar year basis.

12. Pension and Postretirement Benefit Costs (continued)

Change in Plan Assets/ Obligation and Funded Status

The funded status of the plans is measured as the difference between the plan assets at fair value and the PBO for Pension Benefits or accumulated postretirement benefit obligation (APBO) for Other Postretirement Benefits. The resulting net liability is recorded in Pension and postretirement benefit liability on the Combined Balance Sheets. The following shows changes in the benefit obligation, plan assets and funded status (in thousands):

			JL	ine 30		
	Pension	Benefits		tretirement efits		Total
	2023	2022	2023	2022	2023	2022
Change in Benefit Obligation						
Benefit obligation at end of prior year	\$ 3,150,802	\$ 3,889,437	\$ 119,249	\$ 140,751	\$ 3,270,0	
Service costs	49,444	73,506	2,184	2,719	51,6	
Interest costs	149,557	115,364	5,414	3,940	154,9	
Retiree drug subsidy		N/A N/A	(137) 791	(175)	· ·	37)(175)91699
Plan participants' contributions Net actuarial (gain)/loss	(315,079)	N/A (822,391)	(12,051)	699 (19,045)	ر (327,1	
Benefits paid	(114,089)	(105,114)	(12,031) (9,707)	(19,043) (9,640)	(123,7	, , ,
Benefit obligation at end of year	\$ 2,920,635	\$ 3,150,802	\$ 105,743	\$ 119,249	\$ 3,026,3	
Denent Obligation at end of year	φ2,920,035	φ,130,002	φ <u>105,745</u>	φ <u>119,249</u>	φ 3,020,3	<u>70</u>
Change in Plan Assets						
Fair value of plan assets at beginning of						
year	\$ 2,985,879	\$ 3,181,023	\$-	\$-	\$ 2,985,8	79 \$ 3,181,023
Actual return on assets	(7,493)	(123,932)	-	-	(7,4	, , ,
Company contributions	16,953	33,902	9,053	9,116	26,0	
Retiree drug subsidy	-	-	(137)	(175)	,	37) (175)
Plan participants' contributions	-	-	791	699		91 699
Benefits paid	(114,089)	(105,114)	(9,707)	(9,640)	(123,7	
Acquisitions	-	-	-	-	-	
Fair value of plan assets at end of year	\$ <u>2,881,250</u>	\$ <u>2,985,879</u>	<u>\$ -</u>	<u>\$ -</u>	\$2,881,2	<u>50</u>
Funded Status						
Projected benefit obligation/accumulated		• (• (• • • • • • • • • • • • • • • • • • •		A ((A A A A)	A (A A A A A	
postretirement benefit obligation	\$ (2,920,635)	\$ (3,150,802)	\$ (105,743)	\$(119,249)	\$ (3,026,3	, , ,
Plan assets at fair value	2,881,250	2,985,879	-	-	2,881,2	
Funded status at end of year	\$ <u>(39,385</u>)	\$ <u>(164,923</u>)	\$ <u>(105,743</u>)	\$ <u>(119,249</u>)	(145,1	, , ,
Other retirement programs					(118,9	
Total accrued retirement benefits					(264,1	27) (394,219)
Less: Current portion included in Accur	ed expenses				8,9	58 8,958
Pension and post retirement liability					\$ (255,1	<u>69</u>) \$ <u>(385,261</u>)

12. Pension and Postretirement Benefit Costs (continued)

The Accumulated Benefit Obligation for the Pension Benefits was \$2,742,093,000 and \$2,913,123,000 at June 30, 2023 and 2022, respectively.

For the year ended June 30, 2023, the net actuarial gain in the Benefit Obligation for the Pension Benefits was primarily attributable to an increase in the discount rate and demographic changes, while for the year ended June 30, 2022, the net actuarial gain in the Benefit Obligation for the Pension Benefits was primarily attributable to an increase in the discount rate and cash balance conversion assumption.

Net Periodic Benefit Cost

The components of the net periodic benefit cost for pension benefits and other postretirement benefits are as follows (in thousands):

	June 30													
	Other Postretirement													
		Pension	Ber	nefits		Ben	efits		Total					
		2023		2022	2023			2022	2023		2022			
Service cost	\$	49,444	\$	73,506	\$	2,184	\$	2,719 \$	51,628	\$	76,225			
Interest cost		149,557		115,364		5,414		3,940	154,971		119,304			
Expected return on plan assets		(174,230)		(194,223)		-		-	(174,230)		(194,223)			
Amortization of														
Net prior service costs		-		-		(325)		(339)	(325)		(339)			
Net losses		-		22,054		(868)		311	(868)		22,365			
Net periodic benefit cost	\$	24,771	\$	16,701	\$	6,405	\$	6,631 \$	31,176	\$	23,332			

Net Assets Without Donor Restriction

UPHS recorded the following year-end valuation adjustments to its Pension and Other Postretirement Benefit Plans in the Pension and other postretirement plans adjustments in the Combined Statements of Operations (in thousands):

					Jun	e 30						
	Pension Benefits				Other Postretirement Benefits				Total			
		2023		2022	 2023		2022		2023		2022	
Net assets without donor restriction												
Net actuarial loss	\$	45,590	\$	(87,766)	\$ 31,590	\$	20,407	\$	77,180	\$	(67,359)	
Net prior service costs		-		-	 1,322		1,647		1,322		1,647	
Accumulated net assets without donor restriction		45,590		(87,766)	 32,912		22,054		78,502		(65,712)	
Adjustment to net assets without donor restriction	\$	(133,356)	\$	(526,289)	\$ (10,858)	\$	(19,017)	\$	(144,214)	\$	(545,306)	

12. Pension and Postretirement Benefit Costs (continued)

Actuarial Assumptions

The expected long-term rate of return on plan assets is management's best estimate of the average investment return expected to be received on the assets invested in the plan over the benefit period. The expected long-term rate of return on plan assets has been established by considering historical and future expected returns of the asset classes invested in by the pension trust, and the allocation strategy currently in place among those classes.

	Pension Benefits		Other Postretirement Benefits	
-	2023	2022	2023	2022
Weighted-average assumptions used to determine benefit obligation at year end				
Discount rate	5.46 %	4.71 %	5.53 %	4.72 %
Rate of compensation increase	3.22	3.20	3.22	3.20
Cash balance interest credit rate		4.00/6.00		0.00
Weighted-average assumptions for net periodic benefit cost				
Discount rate	4.71/5.39	2.64 - 3.12	4.72 %	2.89 %
Expected long-term return on plan assets	6.90/6.75	4.50 - 7.50	N/A	N/A
Rate of compensation increase	3.20	3.21	3.20	3.21
Cash balance interest credit rate	4.00/6.00	4.00/6.00	N/A	0.00
Assumed health care trend rates Health care cost trend rate assumed for next fiscal year (pre-65/post-65) Rate to which the cost trend rate is assumed to decline			5.36%/5.37%	5.36%/5.37%
(the ultimate trend rate)			4.00%	4.00%
Ultimate trend rate is reached in fiscal year			2047	2047
Medicare Part B trend rate assumed for next fiscal year			4.95%	4.98%
Ultimate trend rate			4.00%	4.00%
Ultimate trend rate is reached in fiscal year			2047	2047
Assumed prescription drug trend rates at June 30 Health care cost trend rate assumed for next fiscal year Rate to which the cost trend rate is assumed to decline			5.83%	5.83%
(the ultimate trend rate)			4.00%	4.00%
Ultimate trend rate is reached in fiscal year			2047	2047

Expected Contributions

UPHS expects to contribute \$16,916,000 and \$8,937,000 for pension benefits and other postretirement benefits, respectively, during the fiscal year ending June 30, 2024.

12. Pension and Postretirement Benefit Costs (continued)

Expected Benefit Payments (in thousands):

	Pension Benefits	Other Post Retirement Benefit Before Medicare Part D Subsidy	Medicare Part D Subsidy
June 30, 2024	144,638	9,012	(75)
June 30, 2025	148,653	9,083	(78)
June 30, 2026	156,597	9,144	(81)
June 30, 2027	164,430	9,121	(83)
June 30, 2028	172,271	9,134	(84)
June 30, 2029 to June 30, 2033	962,301	44,148	(422)

Plan Assets

The principal investment objectives for the pension plans are: to ensure the availability of funds to pay pension benefits as they become due under a broad range of future economic scenarios; to maximize long-term investment returns with an acceptable level of risk based on the pension obligations; and to invest the pension trust in a diversified manner.

UPHS uses the University Office of Investments to manage the day-to-day activities of the investments of the pension. The investments are made in accordance with policies set out by the Investment Board which has been appointed by the Trustees. The pension benefit investments are similar in nature to those investments discussed in Note 2 – Significant Accounting Policies. However, the actual allocations to specific investments within each asset class may vary due to certain restrictions imposed by investment managers and ERISA regulations.

12. Pension and Postretirement Benefit Costs (continued)

A summary of plan assets, measured at fair value, as of June 30, 2023 and 2022 is as follows (in thousands):

					In	vestments	
	 Level 1	 Level 2	I	Level 3		at NAV	 2023
Assets							
Short-term investments Equity investments	\$ 107,503	\$ -	\$	-	\$	-	\$ 107,503
US equities	30,419	-		-		136,200	166,619
International equities	-	-		-		157,063	157,063
Emerging markets equities	-	-		-		31,795	31,795
Debt investments							
US Treasuries and Agencies	1,138,772	-		-		-	1,138,772
Corporate bonds	-	23		-		-	23
Absolute return	-	-		-		596,572	596,572
Real assets	16,784	-		-		171,690	188,474
Private equity	 -	 -		-		507,400	 507,400
	\$ 1,293,478	\$ 23	\$	-	\$	1,600,720	\$ 2,894,221
Liabilities							
Derivative instruments							
Options	\$ 	\$ 12,972	\$	-	\$	-	\$ 12,972
	\$ -	\$ 12,972	\$	-	\$	-	\$ 12,972

	 Level 1	 Level 2	 _evel 3	lr 	ivestments at NAV	 2022
Assets						
Short-term investments	\$ 202,077	\$ -	\$ -	\$	-	\$ 202,077
Equity investments						
US equities	27,843	-	-		133,219	161,062
International equities	17,833	-	-		196,037	213,870
Emerging markets equities	-	-	-		166,740	166,740
Debt investments						
US Treasuries	749,872	-	-		-	749,872
Corporate bonds	89,031	21	-		-	89,052
Absolute return	-	-	-		662,583	662,583
Real assets	47,629	-	1,419		170,741	219,789
Private equity	 -	 -	 -		520,834	 520,834
	\$ 1,134,285	\$ 21	\$ 1,419	\$	1,850,154	\$ 2,985,879
Liabilities Derivative instruments						
Options	\$ -		\$ -	\$	-	\$ -
	\$ -	\$ -	\$ -	\$	-	\$ -

12. Pension and Postretirement Benefit Costs (continued)

As of June 30, 2023, the plan has unfunded commitments to limited partnerships totaling \$269,263,000, which are expected to be called over the next several years.

Transfers between leveled assets are based on the actual date of the event which caused the transfer. As of June 30, 2023 and 2022 there were no transfers between Level 1 and 2.

Allocation of Plan Assets:

	Pension Benefits									
	Target	2023	2022							
Short-term investments	0.0 %	3.3%	6.7%							
Equity investments										
US equities	5.0 %	5.8%	5.4%							
International equities	6.0 %	5.5%	7.2%							
Emerging markets equities	6.0 %	1.1%	5.6%							
Debt investments										
US Treasuries	30.0 %	39.5%	25.1%							
Corporate bonds	0.0 %	0.0%	3.0%							
Absolute return	22.0 %	20.7%	22.2%							
Real assets	10.0 %	6.5%	7.4%							
Private equity	21.0 %	17.6%	17.4%							
	100.0 %	100.0%	100.0%							

13. Net Patient Revenue by Payer

	2023	2022
Medicare (including Managed Medicare)	34 %	33 %
Medicaid (including Managed Medicaid)	12	13
Managed care	33	33
Blue cross	16	16
Commercial	4	4
Self pay	1	1
	100 %	100 %

14. Concentrations of Credit Risk

UPHS grants credit without collateral to its patients, most of whom are local residents and are insured under third party payer agreements. The mix of receivables from patients and third party payers at June 30, 2023 and 2022, respectively, is as follows:

	2023	2022
Medicare	14 %	15 %
Medicaid	3	2
Managed care (including Managed Medicare and Medicaid)	53	51
Blue cross	13	13
Commercial	12	13
Self pay	5	6
	100 %	100 %

15. Lease Commitments

UPHS leases real estate and equipment under operating leases expiring through April 2107. Under the newly adopted accounting standard for leases, a lease conveys the right to control the use of an identified asset for a period of time in exchange for consideration. On the Combined Balance Sheets, lessees are required to record Right-of-Use assets, representing the right to use the underlying assets for the lease term, and Lease Liabilities, representing the obligation to make lease payments arising from the lease based on the present value of lease payments over the lease term. UPHS has made the following elections: (1) to adopt a package of practical expedients relating to reassessment, (2) to exclude leases with a term of less than one year, and (3) to use an incremental borrowing rate for discounting leases, as applicable. Right-of-Use assets recorded in Other assets were \$301,126,000 and \$314,714,000 and Lease Liabilities recorded in Accrued expenses and other liabilities were \$304,297,000 and \$321,843,000, as of June 30, 2023 and 2022, respectively. At June 30, 2023, the weighted average remaining lease term was 9.4 years and the weighted average discount rate was 2.2%. Rental expense is included in Supplies and other expenses on the Combined Statements of Activities. Rental expense totaled \$100,884,000 and \$99,213,000, while amortization of Right-of-use asset was \$43,800,000 and \$44,189,000 for the year ended June 30, 2023 and 2022, respectively.

A summary of future minimum payments under operating leases at June 30, 2023, is as follows (in thousands):

2024 2025 2026 2027 2028 Thereafter	\$ 49,247 50,449 41,780 35,086 29,913 154,080
Total lease payments Less: Imputed interest Total future lease payments	\$ 360,555 (56,258) 304,297

16. Medical Professional Liability Claims

UPHS is insured for medical professional liability claims through the combination of the Medical Care Availability and Reduction of Error Fund (Mcare - formally the Medical Professional Liability Catastrophe Loss Fund of the Commonwealth of Pennsylvania - CAT Fund), various commercial insurance companies, and risk retention programs.

Mcare levies health care provider surcharges, as a percentage of the Pennsylvania Joint Underwriters Association (JUA) rates for basic coverage, to pay claims and pay administrative expenses of the Mcare participants. These surcharges are recognized as expenses in the period incurred. In March 2002, the Pennsylvania General Assembly approved reforming the Commonwealth's medical malpractice insurance system. Mcare operates on a pay-as-you-go basis and no provision has been made for any future Mcare assessments in the accompanying combined financial statements, as UPHS' portion of the unfunded Mcare liability cannot be estimated.

UPHS retains insurance for primary and excess coverage, in addition to the self-insured amounts. The coverage provided by the captive is done through its purchase of commercial insurance. The excess professional liability coverage is provided on a claim-made basis.

UPHS funded RRG/Captive and Lancaster General Insurance Company, Ltd. (LGI), for purposes of administering its risk retention program and covering its primary layer exposures. The assets and respective liabilities of risk retentions groups are included in the accompanying combined financial statements. Effective June 30, 2023, Lancaster General Insurance Company was merged into Risk Retention Group (Captive).

UPHS accrues for estimated retained risks arising from both asserted and unasserted medical professional liability claims. UPHS has employed independent actuaries to estimate the ultimate costs, if any, of the settlement of these claims. The estimate of the gross liability and corresponding receivable for unasserted claims arising from unreported incidents is based on analysis of historical claims data by an independent actuary, which is recorded utilizing a 2.25% discount rate at June 30, 2023 and June 30, 2022. Total liability under this program is approximately \$866,118,000 and \$797,620,000 with a corresponding receivable of \$200,145,000 and \$119,795,000 at June 30, 2023 and 2022, respectively.

17. Charity, Uncompensated and Under-Compensated Care

UPHS accepts patients in serious need of professional medical care, independent of their financial status. This definition includes those patients suffering from a medical condition manifesting itself by acute symptoms of sufficient severity (including severe pain) such that the absence of immediate medical attention could reasonably be expected to result in (1) placing the health of the individual (or, with respect to a pregnant woman, the health of the woman or her unborn child) in serious jeopardy, or (2) serious impairment to bodily functions. Accordingly, UPHS provides services to patients, who meet certain criteria under its charity care policy, without charge or at amounts less than UPHS' established rates. Because UPHS does not pursue collections, such amounts have been excluded from net patient service revenue. UPHS estimated \$37,665,000 and \$31,336,000 of costs were incurred during 2023 and 2022, respectively, from providing services to charity patients. The estimated costs of providing charity services are based on data derived from a combination of the UPHS' cost accounting system and the ratio of costs to charges. UPHS also provides care to patients who do not have health insurance or meet the

17. Charity, Uncompensated and Under-Compensated Care (continued)

criteria to qualify for its charity care policy. UPHS pursues collection of these amounts, however certain amounts are deemed to be uncollectible. Implicit price concessions, which reduce net patient service revenue was \$168,068,000 and \$195,591,000 for years ending June 30, 2023 and 2022, respectively.

Additionally, the costs of providing services to eligible welfare recipients, who participate in the Pennsylvania Medical Assistance and local Managed Medicaid programs exceeded reimbursement by \$381,243,000 and \$358,390,000 in 2023 and 2022, respectively. In addition to providing direct patient charity care and in furtherance of its exempt purpose to benefit the community, UPHS operates emergency rooms open to the public 24-hours per day, 7 days per week; maintains research facilities for the study of disease and injuries; provides facilities for teaching and training various medical personnel; facilitates the advancement of medical and surgical education; and provides various community services such as screenings for the detection of breast, colorectal and skin cancer, cancer support groups, a toll free number for cancer information, free immunization shots, training programs for the City Fire and Police Departments, health education classes, speeches, and regularly provides health related information to television and radio news programs and to reporters at newspapers and magazines.

18. Contingencies and Commitments

UPHS is subject to litigation and regulatory investigations that arise in the ordinary course of its business. UPHS is involved in a legal matter whereby a jury awarded \$182,738,000 to a plaintiff in a medical malpractice case against UPHS. UPHS is appealing the verdict. To cover claims arising out of its operations, UPHS maintains various levels of insurance coverage with deductibles that UPHS believes to be sufficient. UPHS cannot assure that professional liability insurance will cover all claims or continue to be available at reasonable costs for UPHS to maintain adequate levels of insurance. In the opinion of management, the outcome of such claims and litigation will not materially affect our combined financial position, results of operations and cash flows.

At June 30, 2023, construction contract commitments are estimated to total \$114,360,000.

UPHS maintains various unused letters of credit with expirations at various dates through fiscal year 2025 totaling \$13,413,000 and \$12,008,000 at June 30, 2023 and 2022, respectively, to cover balances due on construction projects and reinsurance agreements.

19. Liquidity and Availability

As of June 30, 2023, financial assets and liquidity resources available within one year for general expenditure, such as operating expenses, scheduled principal payments on debt and capital construction costs not financed with debt, are as follows (in thousands):

	2023	 2022
Financial assets:		
Cash and cash equivalents	\$875,232	\$ 816,111
Current receivables	1,227,495	1,165,867
Pledge payment available for operations	1,715	2,158
Designated investments and Investments	1,970,093	 2,247,881
Total financial assets available within one year	\$4,074,535	\$ 4,232,017
Liquidity resources		
Bank lines of credit	95,029	 95,291
Total financial assets and liquidity resources available within one year	\$4,169,564	\$ 4,327,308

To manage liquidity, UPHS maintains a line of credit that is drawn upon as needed during the year to manage cash flows. Management has the discretion to utilize the full amount of designated investments, in Assets whose use is limited, for general expenditures.

20. Investment Returns

A summary of the investment return, which is net of external and direct internal investment expenses, for the years ended June 30, 2023 and 2022 is presented below (in thousands).

	 2023	 2022
Interest and dividends	\$ 51,063	\$ 23,676
Net realized changes on investments	82,208	321,546
Changes in unrealized gain/(loss) on investments, other than debt	 (40,001)	 (387,316)
Investment income/(loss), net	93,270	(42,094)
Changes in unrealized gain/(loss) on debt investments	545	(7,021)
Net realized and unrealized gain/(loss) on restricted funds	 8,597	 (39,940)
Total investment return, net	\$ 102,412	\$ (89,055)

21. Subsequent Events

UPHS has evaluated subsequent events through September 28, 2023, which is the date the combined financial statements were issued.

Supplementary Combining Information

University of Pennsylvania Health System Combining Balance Sheet June 30, 2023 (thousands of dollars)

		CPUP	CCA	HUP	Р	PMC	TCCHS	P	PAH - UPHS	LGH	PHCS	Но	ahickon spice/ necare	c	Corporate	RRG/ aptive	Elin	inations	Тс	otal
Assets																				
Current																				
Cash and cash equivalents	\$	-	\$ -	\$-	\$	- \$	-	\$	-	\$ 119,378	\$ 11,028	\$	72,767	\$	672,059	\$ -	\$	- \$		875,232
Due from (to) UPHS central treasury		405,007	32,052	1,092,301		(27,504)	(100,002)		35,511	-	-		31,623		(1,468,988)	-		-		-
Patient receivables, net		76,060	27,174	387,730		100,799	54,527		80,052	197,662	65,104		38,950		-	-		-	1,	028,058
Third party payer receivables		-	-	37,013		1,392	49		1,471	-	-		-		-	-		-		39,925
Assets held for sale		-	-	-		-	-		-	43,369	-		-		-	-		-		43,369
Other current assets		23,303	 3,264	131,559		57,661	19,061		39,419	51,304	18,986		16,044		65,688	100,000		(100,000)		426,289
Total current assets		504,370	 62,490	1,648,603		132,348	(26,365		156,453	411,713	95,118		159,384		(731,241)	100,000		(100,000)	2,	412,873
Assets whose use is limited																				
Held by trustee		118,999	-	2,735		-	-		-	5,475	6,163		-		34,956	-		-		168,328
RRG\Captive		-	-	-		-	-		-	(132)	-		-		-	201,459		-		201,327
Designated		41,000	-	750,386		-	-		97,221	1,494,986	269,552		-		1,218,594	-		-	3,	871,739
Donor-restricted investments		-	 -	170,381		190,421	54,871		341,002	51,930	39,668		1,129		1,268	-		-		850,670
		159,999	0	923,502		190,421	54,871		438,223	1,552,259	315,383		1,129		1,254,818	201,459			5,	092,064
Investments		-							141	-	165		74		125,013					125,393
Property and equipment, net		15,839	40,447	2,853,898		425,479	434,659		218,616	891,904	353,560		5,577		675,064	-		-		915,043
Other assets		59,723	25,167	51,666		139,688	47,663		1,613	64,712	46,868		6,334		340,827	-		-		784,261
Total assets	\$	739,931	\$ 128,104	\$ 5,477,669	\$	887,936 \$	510,828	\$	815,046	\$ 2,920,588	\$ 811,094	\$	172,498	\$	1,664,481	\$ 301,459	\$	(100,000) \$	14,	329,634
Liabilities and Net Assets																				
Current																				
Accounts payable	\$	49	\$ 190	\$ 22	\$	9 \$	8,194	\$	389	\$ 45,805	\$ 13,347 \$	5	347	\$	222,805	\$ -	\$	- \$		291,157
Accrued expenses		145,172	49,991	186,176		59,343	26,124		32,460	100,949	41,098		24,156		383,595	2,107		(100,000)	1	951,171
Current portion of long-term debt		-	-	33,413		6,891	188		5,157	14,536	6,459		118		-	-		-		66,762
Current portion of notes payable		-	-	-		-	-		-	-	-		-		-	-		-		0
Due to the University of Pennsylvania		-	-	-		-	-		-	-	-		-		1,198	-		-		1,198
Liabilities associated with assets held for sale		-	-	-		-	-		-	19,046	-		-		-	-		-		19,046
 Third party payer settlements 		-	 -	14,780		4,183	1,824		1,346	5,585			-		-	-				27,718
Total current liabilities		145,221	50,181	234,391		70,426	36,330		39,352	185,921	60,904		24,621		607,598	2,107		(100,000)	1,	357,052
Long-term debt, net of current portion		-	-	1,197,707		78,556	359,380		83,809	328,867	247,933		-		168,333	-		-	2,	464,585
Due to the University of Pennsylvania		-	-	-		-	-		-	-	-		-		35,000	-		-		35,000
Third party payer settlements, net of current portion		(5)	-	-		-	-		5,291	-	1,094		5,446		10,958	-		-		22,784
Other liabilities		58,118	20,378	50,435		78,530	39,597		1,346	29,209	25,695		5,989		655,024	273,710		-		238,031
Pension and postretirement benefit liability		118,999	 -	-			-		-	851	0				135,319	-				255,169
Total liabilities		322,333	70,559	1,482,533		227,512	435,307		129,798	544,848	335,626		36,056		1,612,232	275,817		(100,000)	5,	372,621
Net assets																				
Net assets without donor restriction		417,569	56,948	3,817,494		470,387	20,650		344,246	2,324,137	433,273		133,469		51,160	25,642		-	8,	094,975
Net assets with donor restrictions	_	29	 597	177,642		190,037	54,871		341,002	 51,603	42,195		2,973		1,089	-		-		862,038
Total net assets		\$417,598	 \$57,545	\$3,995,136		\$660,424	\$75,521		\$685,248	\$ \$2,375,740	\$475,468		\$136,442		\$52,249	\$25,642		\$0	\$8.	957,013
Total liabilities and net assets	\$		\$ 		\$	887,936 \$	510,828	\$		2,920,588	\$ 811,094		172,498	\$	1,664,481	\$ 301,459	\$	(100,000) \$		329,634
	-																			

University of Pennsylvania Health System Combining Balance Sheet June 30, 2022 (thousands of dollars)

	CP	UP	сс	A	HUP		РРМС	т	CCHS	PA	NH - UPHS		LGH	PHCS	н	sahickon ospice/ omecare	с	orporate	RRG/ Captive	Elimina	tions	Total
Assets Current																						
Cash and cash equivalents Due from (to) UPHS central treasury	\$	- 165,113	\$	- 30,473	\$ 755,14	- \$	- 12,816	\$	- (46,239)	\$	- 44,863	\$	92,597	\$ 56,149	\$	51,095 31,623	\$	616,270 (1,193,790)	\$ -	\$	-	\$ 816,111
Patient receivables, net		76,547		30,019	388,83		107,590		55,410		74,515		- 183,871	- 57,443		38,708		(1,130,730)	-		-	1,012,942
Third party payer receivables		-		-	3,24	3	1,358		101		1,468		-	-		-		-	-		-	6,175
Other current assets		19,242		3,655	131,31		50,926		18,352		35,295		70,486	 17,889		12,246		45,389	 -		-	404,796
Total current assets	4	60,902		64,147	1,278,54	1	172,690		27,624		156,141	-	346,954	 131,481		133,672		(532,131)	 -		-	2,240,024
Assets whose use is limited Held by trustee RRG\Captive	1	10,047		-	7,190)	-				-		8,483 58,471	5,805		-		33,694	- 245,785		-	165,219 304,256
Designated		- 36,000			944,468	- 3			-		96,239		1,539,281	- 268,091		-		- 1,210,858	240,700			4,094,937
Donor-restricted investments		-		-	172,48		196,050		21,348		348,736		49,072	 29,662		980		2,215	 		-	820,548
	1	46,047		-	1,124,143	3	196,050		21,348		444,975		1,655,307	303,558		980		1,246,767	 245,785		-	5,384,960
Investments		-		-		-			-		141		66,907	170		70		124,770	-		-	192,058
Property and equipment, net		14,153		40,487	2,970,503		388,371		427,675		225,638		910,565	360,985		5,520		605,436	-		-	5,949,333
Other assets		61,110		26,124	56,23	2	127,754		37,382		2,259		68,567	 53,290		(121)		197,323	 -		-	629,919
Total assets	\$6	82,212	\$ 1	30,758	\$ 5,429,422	2 \$	884,865	\$	514,029	\$	829,154	\$	3,048,300	\$ 849,484	\$	140,121	\$	1,642,165	\$ 245,785	\$	-	\$ 14,396,294
Liabilities and Net Assets Current																						
Accounts payable	\$		\$			4) \$	(18)	\$	2,018	\$	605	\$	47,949	\$ 15,170	\$	285	\$	225,634	\$ -	\$	-	\$ 291,658
Accrued expenses Current portion of long-term debt	1	49,067		53,582	179,39 27,00		60,227 7,195		36,769		41,212 4,870		136,930 5,611	46,223 6,169		24,333		365,976 4,952	(3,071)		-	1,090,645 55,802
Due to the University of Pennsylvania		(224)		-	21,000	-	-		-		-,070		-	- 0,105		-		1,527	-		-	1,303
Third party payer settlements		<u> </u>			70,282	2	30,375		9,293		10,052		31,780	 12,385		-			 -		-	164,167
Total current liabilities	1	48,857		53,617	276,650)	97,779		48,080		56,739		222,270	79,947		24,619		598,089	(3,071)		-	1,603,575
Long-term debt, net of current portion		-		-	1,242,30	1	88,055		349,853		89,783		354,810	255,916		-		161,132	-		-	2,541,850
Third party payer settlements, net of current portion		(5)		-		-	-		-		5,291		-	2,642		4,677		8,181	-		-	20,786
Due to the University of Pennsylvania		-		-	FF 70		-		-		-		-	-		-		40,000	-		-	40,000
Other liabilities Pension and postretirement benefit liability		59,292 10,047		21,743	55,76	-	83,356		31,275		1,746		94,681 115,980	31,439 8,906		64 -		578,278 150,328	230,888		-	1,188,530 385,261
Total liabilities		18,191		75,360	1,574,71		269,190		429,208		153,559		787,741	 378,850		29,360		1,536,008	 227,817			 5,780,003
Net assets				,	.,,		200,100		.20,200					 5.0,000		20,000		.,	 			-,
Net assets without donor restriction	3	63,971		54,932	3,676,07	9	420,489		41,618		326,860		2,211,632	434,470		109,190		104,117	17,968		-	7,761,326
Net assets with donor restrictions		50		466	178,624		195,186		43,203		348,735		48,927	 36,163		1,571		2,040	 		-	854,965
Total net assets	3	64,021		55,398	3,854,703	3	615,675		84,821		675,595		2,260,559	 470,633		110,761		106,157	 17,968		-	8,616,291
Total liabilities and net assets	\$6	82,212	\$ 1	30,758	\$ 5,429,42	2 \$	884,865	\$	514,029	\$	829,154	\$	3,048,300	\$ 849,483	\$	140,121	\$	1,642,165	\$ 245,785	\$	-	\$ 14,396,294

	CPUP	CCA		HUP	PPMC	TCCHS	PAH - UPHS	LGH	PHCS	Wissahickon Hospice/ Homecare	Corporate	RRG/ Captive	Eliminations	Total
Revenues														
Net patient service revenue	\$ 685,396 \$	318,984	\$	3,187,784 \$	923,296 \$	473,604	\$ 740,217 \$	1,514,239 \$	573,256	\$ 310,590 \$	\$	-	S - S	8,727,443
Other revenue and support	 135,962	41,582		596,444	228,048	20,249	71,163	173,646	19,934	22,139	59,815	46,562	(168,290)	1,247,254
Total revenues	821,358	360,566		3,784,228	1,151,344	493,853	811,380	1,687,885	593,190	332,729	59,892	46,562	(168,290)	9,974,697
Expenses														
Salaries and wages	813,921	217,509		970,537	334,772	193,991	281,437	730,809	260,421	138,983	321,303		-	4,263,683
Employee benefits	149,639	47,155		282,336	94,337	49,103	78,159	188,711	60,267	36,534	78,775	•	-	1,065,016
Supplies and other expenses	92,857	105,033		1,413,382	454,147	186,139	283,571	600,569	191,679	127,471	337,022	780	1,135	3,793,785
Corporate services/inter-entity support	(333,973)	(21,895	/	703,758	175,935	54,299	124,165	94,523	51,728	13,462	(739,139)	•	(122,863)	-
Depreciation and amortization	3,914	3,240		164,399	33,438	26,086	27,178	72,177	31,058	1,329	51,702	-	-	414,521
Malpractice	41,390	7,672		21,093	7,267	1,520	6,901	10,301	1,832	52	5	45,782	(46,562)	97,253
Interest	-	-		55,441	2,821	4,733	2,825	7,180	9,451	•	(902)	•	-	81,549
Pererlman School of Medicine (PSOM) support	 <u> </u>	-		12,058	3,632		· · ·	· ·	· ·	· ·	5,027	· ·		20,717
Total expenses	 767,748	358,714		3,623,004	1,106,349	515,871	804,236	1,704,270	606,436	317,831	53,793	46,562	(168,290)	9,736,524
Excess (deficit) of revenue over expenses from operations	53,610	1,852		161,224	44,995	(22,018)	7,144	(16,385)	(13,246)	14,898	6,099	-		238,173
Nonoperating gains (loss)														
Investment Income, net	14,844	184		41,658	(223)	(374)	5,117	32,496	3,097	2,149	(13,352)	7,674	-	93,270
Other non-operating (loss)/income, net	0	(20)	15,915	5,125	(209)	5,381	(24,944)	(745)	(965)	6	0	-	(456)
Loss on extinguishment of debt		-		•	•	•	-	-	•	•	-	•	-	-
Excess (deficit) of revenue over expenses	68,454	2,016		218,797	49,897	(22,601)	17,642	(8,833)	(10,894)	16,082	(7,247)	7,674		330,987
Change in unrealized gain (loss) on investments	-	-					-	-			545		-	545
Transfers to PSOM and University, net	(28,953)	-		(95,497)	-		(703)	-		(164)	(36,603)		-	(161,920)
Transfers to the other Health System entities	14,098	100		395		-	-	121,327	9,655	8,359	(153,934)		-	•
Net assets released from restrictions for capital	-	(100)	17,720		1,634	449	77	43		•		-	19,823
Pension and other postretirement plan adjustments	 -	-		-	-	-	<u> </u>	(66)	-	-	144,280	-		144,214
Increase/(decrease) in net assets without donor restriction	\$ 53,599 \$	2,016	\$	141,415 \$	49,897 \$	(20,967)	\$ 17,388 \$	112,505 \$	(1,196)	\$ 24,277	\$ (52,959) \$	7,674	s - s	333,649

University of Pennsylvania Health System Combining Statement of Operations Year Ended June 30, 2022 (thousands of dollars)

		CPUP	CCA	HUP		PPMC	TCCHS	PÆ	H - UPHS	LGH	PHCS	Ho	sahickon ospice/ mecare	Co	orporate	 RG/ otive	Eliminat	tions	Total
Revenues																			
Net patient service revenue	\$	660,824	\$ 294,312 \$	2,898,482	\$	869,232	\$ 427,937	\$	694,387	\$ 1,464,991	\$ 523,076	\$	270,982	\$	166	\$	\$		\$ 8,104,389
Other revenue and support		127,654	 33,369	523,129		187,692	23,061		72,071	 176,320	 17,637		13,163		57,514	46,562	(17	8,154)	 1,100,018
Total revenues	_	788,478	 327,681	3,421,611	_	1,056,924	450,998		766,458	 1,641,311	 540,713		284,145		57,680	 46,562	(17	8,154)	 9,204,407
Expenses																			
Salaries and wages		759,785	191,188	918,422		320,217	184,636		275,071	700,029	233,721		124,409		336,003	-		-	4,043,481
Employee benefits		139,847	40,017	273,511		91,377	44,723		76,346	179,822	52,636		33,997		78,219	-		-	1,010,495
Supplies and other expenses		107,689	93,365	1,251,118		400,023	168,215		268,313	560,762	174,892		100,161		323,137	780	'	8,619)	3,439,836
Corporate services/inter-entity support		(309,952)	(16,936)	685,479		163,209	54,385		128,692	80,854	49,246		13,079		(723,796)	•	(12	4,260)	•
Depreciation and amortization		4,299	2,860	141,260		31,074	25,407		28,379	67,999	35,155		1,049		50,476	•		-	387,958
Malpractice		41,590	7,970	20,805		6,704	1,698		6,492	11,480	2,249		63		(15,000)	45,782	(4	5,275)	84,558
Interest		•	•	41,093		4,078	5,099		2,860	10,027	7,148		-		(292)	•		•	70,013
Pererlman School of Medicine (PSOM) support			 <u> </u>	11,955		3,699			-	 -	 -		-		4,934	 <u> </u>			 20,588
Total expenses		743,258	 318,464	3,343,643		1,020,381	 484,163		786,153	 1,610,973	 555,047		272,758		53,681	 46,562	(17	8,154)	 9,056,929
Excess (deficit) of revenue over expenses from operations		45,220	9,217	77,968		36,543	(33,165)		(19,695)	30,338	(14,334)		11,387		3,999	-		-	147,478
Nonoperating gains (loss)																			
Investment Income, net		13,906	1,745	55,425		2,481	349		2,852	(30,666)	2,150		1,472		(91,974)	167		•	(42,093)
Other non-operating (loss)/income, net Gain/(Loss) on extinguishment of debt		(9)	(3,474)	27,664		10,203	6,058		11,547	7,081	2,085		18		(6,245) 3.398	-		-	54,928 3,398
Excess (deficit) of revenue over expenses		59,117	 7,488	161,057		49,227	 (26,758)	· <u> </u>	(5,296)	 6,753	 (10,099)		12,877		(90,822)	 167			 163,711
Change in unrealized gain (loss) on investments		•	-							•	•		,		(7,021)				(7,021)
Transfers to PSOM and University, net		(45,856)		(75,945))				(635)				(160)		(36,748)				(159,344)
Transfers to the other Health System entities		15.298		1,064	/				(000)				(100)		(16,362)				-
Net assets released from restrictions for capital		.,		52			78		19	726	23				(898
Pension and other postretirement plan adjustments			 <u> </u>			-			-	 69,612	 (4,140)		-		479,834	 -		-	 545,306
Increase/(decrease) in net assets without donor restriction	\$	28,559	\$ 7,488 \$	86,228	\$	49,227	\$ (26,680)	\$	(5,912)	\$ 77,091	\$ (14,216)	\$	12,717	\$	328,881	\$ 167	\$	-	\$ 543,550